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Preface 
The new field of nanotechnology, has opened up rapid advances in science 
and technology, and creates myriad new opportunities for advances in medical 
science and disease treatment in human health care. Since adequate cancer 
therapeutics remains elusive, it is required to develop new methods for efficient 
cancer diagnosis and therapy. Nanoparticle-mediated site targeted drug delivery offers 
an attractive option to enhance the therapeutic efficacy by delivering optimal drug 
concentrations to the targeted cancer cells, and with reduced toxicity to the healthy 
tissues. The integration of nano-materials into cancer therapeutics provides a way of 
smart drug delivery with high target specificity and greater therapeutic efficacy. 
Carbon nanotubes (CNTs), due to their unique intrinsic physiochemical properties are 
extensively explored as novel drug delivery systems for therapy and diagnosis. 
In this thesis entitled “Carbon Nanotubes as a Theragnostic Tool Against 
Breast Cancer” comprises of seven chapters and mainly focuses on the use of carbon 
nanotubes as potential biomedical materials, which show great potential as a targeted 
and effective drug delivery system for cancer therapy, by grafting it with cell-specific 
receptors and intracellular targeting molecules.  
Chapter 1 explains the scope of nanotechnology in developing target specific 
carriers to achieve higher therapeutic efficacy, which will significantly contribute to 
the next generation of medical care and pharmaceuticals in the areas of disease 
diagnosis, disease prevention and most importantly cancer therapy. This review 
introduces specific physical and chemical properties of a series of nano-materials, 
such as nanoparticles, micelles, dendrimers, and with more emphasis on carbon 
nanotubes, which show great potential as effective drug delivery systems for cancer 
therapy. In addition to the ability of nanotubes to act as carriers for a wide range of 
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therapeutic molecules, they are also exploited for the use in photo-thermal destruction 
of cancer cells. Specifically, this article focuses on the current status, recent 
advancements, potentials and limitations of functionalized carbon nanotubes as 
targeted drug delivery carriers for efficient cancer nano-therapeutics. 
Chapter 2 discusses the principles behind various instruments and techniques 
used for characterization of nano-sized structures, and for analysis of biological 
samples used in our research work. 
Chapter 3 explains about a targeted drug delivery system (DDS) based on 
SWCNTs biofunctionalized with polyethylene glycol (PEG), conjugated with folic 
acid (FA) as targeting moiety and loaded with anticancer drug doxorubicin (DOX) for 
selective killing of tumor cells. The prepared nanotubes were characterized for their 
morphological features and their elemental composition. In this study, in vitro drug 
release analysis showed that the drug (DOX) binds at physiological pH (pH 7.4) and 
is released at a lower pH (lysosomal pH 4.0), which is the characteristic pH of the 
tumor environment. A sustained release of DOX from the SWCNTs was observed for 
a period of three days, which effectively caused the death of the breast cancer cells. 
The nanotubes were incubated with breast cancer cells and their biocompatibility and 
anti-proliferative effects were analyzed. We found that the targeted nanotubes were 
non-toxic to normal cells but toxic to tumor cells. Cellular uptake of the targeted 
nanotubes was studied in vitro using confocal microscopy. Time dependent drug 
effect was also studied on normal cells and tumor cells. Our results show significant 
internalization and retention of the nanotubes inside the tumor cells, inducing 
apoptosis. The results indicate that this study with folate conjugated and DOX loaded 
nanotubes can be a promising targeted delivery vehicle for cancer therapy. 
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Chapter 4 demonstrates that SWCNTs have a strong optical absorbance in the 
near-infrared (NIR) region. An approach utilizing the photo-thermal effect of single-
walled carbon nanotubes (SWCNTs), in combination with folate as a targeting moiety 
and DOX an anticancer drug doxorubicin, for selective and accelerated destruction of 
breast cancer cells is demonstrated. The results of our study show that, under laser 
irradiation at 800 nm, SWCNTs showed strong light-heat transfer characteristics. 
These optical properties of SWCNTs provide an opportunity for photo-thermal 
ablation in cancer treatment. Our observation also showed that the internalization and 
uptake of folate conjugated nanotubes into cancer cells was by a receptor mediated 
endocytosis mechanism. In our in vitro experiments, laser effectively caused 
destruction of cancer cells while sparing the normal cells. When the above laser effect 
was combined with DOX conjugated SWCNTs, an enhanced and accelerated killing 
of breast cancer cells was noted. Thus, this targeting nano drug delivery system 
(NDDS) could effectively kill and suppress the growth of breast cancer cells, showing 
much higher pharmaceutical efficiency compared to free DOX. This study suggests 
that Laser + drug + SWCNTs could prove to be a promising selective modality with 
high treatment efficacy and low side effects for future cancer therapy. 
In Chapter 5 we present a dual drug delivery system consisting of PEG 
modified SWCNTs conjugated with FA and loaded with two anticancer drugs (DOX) 
and paclitaxel (PTX), forming DOX-PTX-FA-PEG-SWCNT conjugate. The 
combination of two or more therapeutic drugs is a feasible means to overcome the 
limitations of single chemotherapeutic drug in anti-tumor treatment, such as 
development of high toxicity, drug resistance, and limited regime of clinical uses. The 
prepared nanotubes were characterized for their morphological features and their 
elemental composition. Independent and combined drug release behaviors of the 
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drugs were studied. A time-dependent in vitro cytotoxicity studies were done for 
studying the cancer killing effect in comparison with free PTX and free DOX in 
breast cancer (MCF7) cells. A faster drug release was found to be associated with 
lower pH, which is advantageous for tumor targeted anticancer therapy. Confocal 
studies were carried out to demonstrate cellular uptake of the targeted nanotubes in 
tumor cells, while sparing the normal cells. This efficient suppression in tumor cell 
growth demonstrates a highly synergistic anti-proliferative activity of our developed 
system in breast cancer cells. The effect of this DDS in combination with laser was 
also analyzed, and enhanced destruction of breast cancer cells were observed. This 
nano-carrier might have important potential in clinical implications for co-delivery of 
multiple anti-tumor drugs with different properties. 
Chapter 6 explains the application of another nano-carrier that could be 
utilized as a drug delivery agent in cancer therapy. Here, an anticancer drug loaded 
poly-L-Lactic-co-glycolic acid (PLGA)-lecithin-PEG nanoparticles were synthesized 
and were functionalized with AS1411 anti-nucleolin aptamers for site-specific 
targeting against tumor cells, which over expresses nucleolin receptors. The results of 
this study confirmed that the aptamer-labeled PLGA-lecithin-PEG nanoparticles are 
potential carrier candidates for differential targeted drug delivery. 
Chapter 7 concludes the thesis with the summary and future prospects of this 
research work. 
The need to develop target specific carriers to achieve higher therapeutic 
efficacy with minimal side effects to healthy tissues, is one of the most interesting and 
challenging endeavors faced in the pharmaceutical field. 
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Chapter 1 
Opportunities and challenges of single walled carbon nanotubes in 
cancer therapy 
 
Abstract 
The scope of nanotechnology to develop target specific carriers to achieve higher 
therapeutic efficacy is gaining importance in the pharmaceutical and other industries. 
Specially, the emergence of nanohybrid materials is posed to edge over chemotherapy 
and radiation therapy as cancer therapeutics. This is primarily because nanohybrid 
materials engage controlled production parameters in the making of nanoparticles 
with specific size, shape and other essential properties. It is widely expressed that 
these materials will significantly contribute to the next generation of medical care 
technology and pharmaceuticals in areas of disease diagnosis, disease prevention and 
most importantly cancer therapy. This review firstly introduces the specific physical 
and chemical properties of a series of nanomaterials, such as nanoparticles, micelles, 
dendrimers and carbon nanotubes. It then places great emphasis on the carbon 
nanotubes, which show great potential as effective drug delivery systems for cancer 
therapy, as they can be grafted with cell-specific receptors and intracellular targeting 
molecules for the targeted delivery of therapeutics. In addition to the ability of 
nanotubes to act as carriers for a wide range of therapeutic molecules, they have also 
been exploited for use in photothermal destruction of cancer cells. Specifically, this 
article focuses on the current status, recent advancements, potentials and limitations 
of functionalized carbon nanotubes as targeted drug delivery carriers for efficient 
cancer treatment. 
	   2	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   3	  
Introduction 
Currently available technologies have made enormous advancement in cancer 
research, but an adequate therapy remains elusive.1 Cancer occurs at a molecular level 
when multiple subsets of genes undergo genetic alterations, either by activation of 
oncogenes or inactivation of tumor suppressor genes, allowing cancerous cells to 
grow and divide uncontrollably.2 These processes allow cancer cells to acquire 
properties of malignant proliferations, tissue infiltrations through interactions with 
surrounding stromal cells, dysfunction of organs by the evasion of immune detection, 
self-sufficiency in growth signals and resistance to both anti-proliferative and 
apoptotic agents.3, 4 Also, in vivo delivery of the therapeutic agents has to overcome 
physiological barriers, including hepatic and renal clearance, enzymolysis and 
hydrolysis, as well as endosomal/lysosomal degradation.5, 6 In addition, the efficiency 
of anticancer drugs is limited by their unsatisfactory properties, such as poor 
solubility, narrow therapeutic window, and intensive cytotoxicity to normal tissues, 
which may be the causes of treatment failure in cancer.7 Therefore, it would be 
desirable to develop new methods to detect cancers at their early stage and also design 
novel therapeutic strategies capable of delivering chemical agents and other 
therapeutic materials specifically to tumor locations without affecting healthy 
tissues.8, 9, 10, 11 With the emerging field of nanotechnology, the integration of 
nanomaterial’s into cancer therapeutics is one of the rapidly growing fields in the 
development of nanoparticles, nanostructured surfaces and platforms for rapid and 
early diagnostics, smart drug delivery and for understanding the therapeutic 
efficacy.12, 13 Nanomaterials have sizes ranging from about one nanometer up to 
several hundred nanometers, Materials in this size range exhibit interesting physical 
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properties, presenting new directions for more effective diagnosis and therapy of 
cancer.14, 15 
Types of nanotechnology based nanocarrier systems 
Nanocarriers applied as drug delivery systems are synthesized from organic and 
inorganic materials such as polymeric nanoparticles, micelles, dendrimers, lipid 
nanoparticles, carbon nanotubes, quantum dots, and nanofibers16, 17 (Figure 1). They 
show great potential in cancer therapy by enhancing the performance of medicine and 
reducing side effects to healthy tissues for improved therapeutic efficiency. 
 
Figure 1. Examples of nanomaterials and nanocarrier systems. 16, 24 
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Polymeric nanoparticles 
Polymeric nanoparticles are particles less than 1µm in diameter, synthesized from 
natural or synthetic polymers. Depending on the methods of preparation, matrix-type 
or reservoir-type structure, namely nanospheres or nanocapsules can be obtained.18 
Natural polymers such as albumin, chitosan, heparin and synthetic polymers such as 
N-(2-hydroxypropyl)-methacrylamide copolymer (HPMA), polystyrene-maleic 
anhydride copolymer, polyethylene glycol (PEG), and poly-L-glutamic acid (PGA) 
have been  material of choice for polymeric nanoparticles.19, 20, 21 They are considered 
as the promising carriers for drug delivery because they can improve the specificity of 
drug action by changing their tissue distribution and paharmacokinetics.22 They have 
also played important roles in delivering antitumor drugs in a targeted manner to the 
malignant tumor cells, thereby reducing the systemic toxicity and increasing their 
therapeutic efficacy. These nanoparticles due to the reticulo-endothelial system (RES) 
and the effect of enhanced permeation and retention (EPR) effect, can be used for 
passive delivery to the lymphatic system, brain, arterial walls, lungs, liver, spleen or 
for long-term systemic circulation.3, 22, 23 These nanoparticles are also amendable to 
surface functionalization for active targeting to tumor tissues or cells and for 
stimulus-responsive controlled release of drug.24 
The receptor-mediated endocytosis (RME) reveals the selective recognition, high-
affinity binding, and immediate internalization for the ligands at a cellular level.25 
Various targeting moieties can be attached to the polymer backbone, which acts as a 
secondary uptake mechanism following EPR-based primary accumulation (Figure 2) 
.4, 26 Liang et al. developed paclitaxel-loaded nanoparticles with galactosamine 
conjugated on it for targeting liver cancer cells. The nanoparticles appeared most 
efficient in reducing the size of the tumor when injected into hepatoma-bearing nude 
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mice, through the specific interaction between galactosamine and asialoglycoprotein 
receptors.27 Thermosensitive magnetoliposomes (TMs) encapsulated with 
methotrexate (MTX) can achieve a good magnetic targeting effect and rapid drug 
release in response hyperthermia, which implies their great potential in cancer 
therapy.28 
Micelles 
Spontaneous assembly usually forms polymeric micelles into core-shell structures 
when its concentration is above critical micelle concentration (CMC). They have a 
number of unique features, including nanosize, easy manipulation of surface 
chemistry, core functionalities, as well as ease of fabrication, making them suitable 
carriers for encapsulation, and delivery of water insoluble agents.5 The hydrophobic 
solid-like inner core region serves as a reservoir for hydrophobic drugs, whereas the 
hydrophilic shell region stabilizes the hydrophobic core and renders the polymers 
water-soluble.29 The hydrophilic shell helps the micelles in escaping the recognition 
of RES and prolongs the blood circulation of drugs. The small size (< 100 nm) allows 
the efficient accumulation of micelles in pathological tissues with permeabilized 
vasculature via the enhanced permeability and retention (EPR) effect.30 Mikhail 
presented a detailed review on the density and heterogeneity of the vasculature at 
tumor sites, interstitial fluid pressure, and found that transport of macromolecules in 
the tumor interstitium are responsible for the extravasation of micelles.31 
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Figure 2. Schematic of nanocarrier systems for site-targeted drug delivery. 25 
 
Stimuli-responsive polymeric micelles are often designed for controlled release of 
drug into tumor tissue with external stimuli trigger, like temperature, pH, ultrasound 
and special enzymes.32, 33 Among these stimuli, pH and temperature are 
representative, because the external pH of cancerous tissue tends to be lower and the 
temperature is higher compared to the surrounding normal tissue, which are caused by 
abnormal metabolism of cancer tissues.5 Lower critical solution temperature (LCST) 
polymers, such as poly (N-isopropylacrylamide) (pNIPAAm) with a cloud point 
around 32°C or some other poly (N-alkylacrylamide) compounds, were investigated 
as components of temperature-responsive copolymer micelles.33 The micelles 
exhibited rapid and temperature-responsive drug release in cancer cells, which was 
caused by the destruction of the hydrophobic-hydrophilic balance with the increase of 
temperature. Licciardi et al. synthesized novel folic acid- (FA-) functionalized diblock 
copolymer micelles for target delivery of antitumor drugs, and lowering the solution 
pH to 5 could trigger the rapid release of drug. This strategy combined the targeted 
delivery of therapeutics together with pH-controlled drug release, which provided a 
tumor-selective nanocarrier for the efficient delivery of anticancer drugs (Figure) .34 
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Dendrimers 
Dendrimers are artificial macromolecules with tree-like structures in which the atoms 
are arranged in many branches and sub-branches radiating out from a central core.35, 36 
They are synthesized from branched monomer units in a stepwise manner. Thus, able 
to control their molecular properties, such as size, shape, dimension, and polarity, 
which depend on the branched monomer units.36 They offer unique interfacial and 
functional performance advantages due to their empty internal cavities and surface 
functional groups.37 So they have an enormous capacity for solubilization of 
hydrophobic drugs and can be modified or conjugated with various molecules. Based 
on these specific properties, the dendrimers have shown great development in 
anticancer drug delivery systems.36, 38 To actively target drugs to tumor tissues the 
dendrimers are used for covalent attachment of special targeting moieties, such as 
sugar, folic acid, antibody, biotin, therapeutic drugs and epidermal growth factors.39, 
34, 40, 36, 41 Choi and coworkers synthesized a fifth generation polyamidoamine (G5 
PAMAM) dendrimers conjugated to fluorescein and folic acid, linked together by 
complementary DNA oligonucleotides to produce clustered molecules for targeting 
cancer cells that overexpress the high-affinity folate receptor. In vitro studies 
indicated that the DNA-linked dendrimer clusters could specifically bind to KB cells 
and could be used as imaging and therapeutics agents for cancer therapy.42 
Carbon Nanotubes 
Carbon nanotubes (CNT) are synthetic nanomaterials made from carbon and belong 
to the fullerene family. Carbon nanotubes are made up of thin sheets of benzene ring 
structured carbon rolled up into the shape of a seamless tubular structure. They can be 
classified into two general categories based on their structure: single-walled carbon 
nanotubes (SWCNTs) with a single cylindrical carbon wall having a diameter of 1-2 
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nm, and length ranging from 50 to several hundred nanometers. Multiwalled carbon 
nanotubes (MWCNTs) have multiple walled-cylinders nested within other cylinders 
with a diameter ranging from 5-100 nm.43 Figure 3 CNTs are generally produced by 
three major techniques: electric arc discharge, 44 laser ablation45 and thermal or 
plasma enhanced chemical vapor deposition (CVD) 46. These methods involve 
synthesis at high temperature and pressure in the presence of reaction catalysts, 
leading to fine structures of CNTs along with some impurities like graphite debris and 
catalytic particles. Various methods such as oxidation, acid treatment, 
chromatography, filtration and functionalization are involved in the purification.47 
Compared to other nanomaterials, CNTs have unique physical and chemical 
properties such as high aspect ratio, ultrahigh surface area, light weight and distinct 
optical properties, such as, high absorption in the near-infrared (NIR) range and a 
strong Raman shift, which makes them advantageous for biomedical applications 
linked to detection and imaging.48 The combination of these characteristics makes 
CNT a unique nanomaterial with the potential for diverse applications, in areas of 
gene therapy, drug delivery, thermotherapy, imaging and anticancer treatments, as 
explained in the subsequent sections.25, 49 
 
Figure 3. Structure of single-walled carbon nanotubes (SWCNTs) and multiwalled 
carbon nanotubes (MWCNTs), as well as drug loaded carbon nanotubes (adapted 
from http://www-ibmc.u-strasbg.fr/ict/vectorisation/nanotubes eng.shtml and 
http://www-ibmc.u-strasbgfr/ict/vectorisation/vectorisation eng.shtml). 
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Functionalization of carbon nanotubes for drug delivery and other applications 
CNTs are hydrophobic in nature and thus insoluble in water, which limits their 
application in biomedical and medicinal chemistry. Therefore, various 
functionalization methods like adsorption, electrostatic interaction and covalent 
bonding are being utilized with a number of compounds and polymers to render a 
hydrophilic character to CNTs so as to avoid aggregation and to facilitate their use in 
biomedical applications.1 Covalent modifications are carried out by reacting carbon 
atoms on the sidewall of carbon nanotubes to a therapeutic molecule. In biological 
applications, oxidation and grafting polymers on the sidewalls of carbon nanotubes 
are widely employed. During oxidation, pristine CNTs are refluxed in nitric acid, 
which results in oxygenated functional groups, mainly carboxyl acids.50, 51 Another 
covalent modification of CNTs involves 1, 3-dipolar cycloaddition reactions.52 Using 
this method, azomethineylides are added on the graphite surface of CNTs, forming 
pyrrolidine-fused rings. These covalent modifications lead to the generation of 
various functional moieties on the ends and sidewall of CNTs and enable the 
conjugation of various fluorescent dyes, drugs, and peptides.53, 54 Other biocompatible 
polymers like polyethylene glycol (PEG) can be grafted forming SWCNT-PEG graft 
copolymer that enhances the solubility of the nanotubes.55 Figure 4 Non-covalent 
functionalization of CNTs has also been explored with materials like surfactants, 
natural polymers, synthetic polyelectrolytes and amphiphilic block polymers or 
polymeric micelles. The hydrophobic moiety binds to the CNT sidewalls via π-π 
interactions, helping the CNTs to disperse in aqueous solutions. It was demonstrated 
that the non-covalent conjugation of pyrene with glycodendrimers via π-π stacking on 
the sidewall of CNTs, enhances their water solubility.56 Amphiphilic polymer 
phospholipid linked PEG (PL-PEG) was used to non-covalently bind to the sidewalls 
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of SWCNTs, giving rise to a number of biomedical applications.57 
CNTs as carriers for drugs, genes and proteins in cancer therapy 
Most of the research on CNTs has been focused on their potential for anticancer drug 
delivery. This might be attributed to the transporting capabilities of CNTs combined 
with appropriate surface modification and their unique physiochemical properties, 
which lead to the development of a new kind of nanomaterial for cancer therapy.11 
Drug delivery by CNTs 
Functionalized CNTs can cross the mammalian cell membrane by endocytosis or 
other mechanisms with the help of specific peptides or ligands on their surface to 
recognize cancer-specific receptors on the cell surface.58 Cancer cells overexpress 
folic acid (FA) receptors, and many research groups have designed CNT carriers with 
engineered surfaces to which FA derivatives can be attached. CNTs are used for 
targeting lymph node cancers, as they can be retained in the lymph nodes for longer 
periods of time compared to spherical nanocarriers.59-62 In a recent study, Yang et al.63 
have loaded the anticancer molecule gemcitabine into magnetic MWCNTs and 
injected subcutaneously and, they reported high activity against lymph node 
metastasis in mice. In another study, the poorly water-soluble anticancer drug, 
camptothecin, has been loaded into polyvinyl alcohol-functionalized MWNTs and 
was reported to be potentially effective in the treatment of breast and skin cancers.64 
In another approach, PAA-grafted MWCNTs were prepared and subcutaneously 
injected into the left rear footpad of rat.65 The biopsy result showed that left popliteal 
lymph nodes were blacker than other regions, 24 h after the injection. Biopsy 
experiments did not identify the presence of PAA-g-MWCNTs in the major internal 
organs such as liver, kidney and lung, which suggests that the PAA-g-MWCNTs may 
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have the potential to be used as a vital staining dye and can be used for lymph node 
identification during surgery, even when they are very small.66 
Dhar and coworkers developed the longboat delivery system, (Figure 5) in which 
cisplatin and FA conjugate was attached to a functionalized SWCNT via a number of 
amide bonds to form a “longboat” which is reported to be taken up by cancer cells via 
endocytosis, followed by the release of the drug and its subsequent interaction with 
the nuclear DNA. Another platinum anticancer drug, carboplatin, was incorporated 
into CNT and has been shown to inhibit the proliferation of urinary bladder cancer 
cells in vitro.67 
 
Figure 4. Synthetic scheme of SWNT-PEG graft copolymers. The carboxylic acid 
functionalized Single Wall Carbon Nanotubes (SWNT–COOH) react with oxalyl 
chloride to form the acylchloride intermediate, which is further reacted with PEG to 
form SWNT–PEG. 148 
	  
Figure 5. The “longboat” anticancer system in which one end of the 
chemotherapeutic agent cisplatin is attached from to the FA derivative and the 
opposite end to a SWCNT via an amide link. 67 
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CNTs can carry therapeutic drugs more safely and effectively into the cells, which 
make them ideal candidates for drug delivery. Recently, novel SWCNT- based tumor-
targeted drug delivery systems (DDS) have been developed. These delivery systems 
generally consist of three parts: functionalized SWCNTs, tumor targeting ligands and 
anticancer drugs. The complex is taken up efficiently and specifically by cancer cells 
with subsequent intracellular release of anticancer drugs, which suppressed cancer 
cell growth more effectively than untargeted controls containing the same drug.68 
Hence, with this novel approach, serious and harmful side effects to healthy tissues 
can be avoided. Paclitaxel is a poorly water-soluble anticancer drug. In the 
commercialized paclitaxel product (Taxol), Cremophor EL is used to solubilize the 
drug. Unfortunately, Cremophor EL itself is toxic. Therefore, finding a suitable 
alternative is of high priority. Moreover, the circulation time of Taxol is very short. 
Coating the nanocarriers with hydrophilic polymers such as polyethylene glycol 
(PEG) has been established as a strategy to prolong the circulation of the nanocarrier 
in blood by making the carrier highly evasive to the uptake by the macrophages in 
blood.69, 70 PEGylation of paclitaxel increases the circulation time in the blood over 
Taxol.71 In the research performed by Liu Z. et al., 72 functionalized SWNTs 
conjugated with paclitaxel through branched PEG chains via a cleavable ester bond 
was synthesized. This resultant complex was more effective in suppressing tumor 
growth in vivo than Taxol or paclitaxel-PEG conjugate in a 4T1 breast cancer animal 
model. PEGylation of the nanotubes is able to prolong the circulation time and greatly 
enhance cellular uptake of the drug by the cancer cells. Similar findings of anti- 
cancer activity have been reported when paclitaxel was loaded into PEGylated 
SWCNTs or MWCNTs using HeLa and MCF-7 cancer cell lines.73, 74  
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Multidrug resistance is a significant obstacle to successful anticancer drug therapy 
since the P-glycoprotein transporter can interfere with the accumulation of anticancer 
drugs in the target cells, resulting in reduced effectiveness of therapy.75, 76 Recently, 
confocal microscopy has shown the accumulation of PEGylated MWCNTs in 
multidrug resistant hepatoma cell lines.77 Liu and coworkers reported that although 
PEGylation of SWCNTs can prolong blood circulation time of the associated 
anticancer drug, it may cause an accumulation of the nanotubes in the dermal tissues 
of mice, suggesting that the extend of PEG coating require optimization.78 
Biotin-functionalized SWCNTs conjugated with the anticancer agent taxoid using a 
cleavable linker have also been designed. The drug is transported via endocytosis, 
released in the cell and interacts with microtubules as evaluated by flow cytometry. 
This resulted in the formation of a stable microtubule-taxoid complex, which finally 
caused apoptosis and cell death.74 
A targeted delivery system of FA-tethered SWCNTs-doxorubicin (DOX) has been 
designed. Bioadhesive polymers such as chitosan (CHI) and sodium alginate (ALG) 
were used to enhance the aqueous dispersibility of the nanotubes, while FA was used 
to improve the targeting properties of the nanotubes (Figure 6). Transmission electron 
microscopy (TEM) indicated that the drug was released at the low lysosomal pH of 
the HeLa tumor cells after being transported into the tumor but not at the normal 
physiological pH of 7.4.58 Recently, a novel approach by covalently attaching 
PAMAM dendrimers to FA-treated MWCNTs has been introduced and flow 
cytometry and confocal microscopy indicated possible targeting of cancer cells that 
overexpress FA receptors.79 Li and coworkers designed a novel system referred to as 
“dual-targeted drug nanocarrier” by conjugating MWCNTs with iron nanoparticles 
and folate moiety. This system was efficiently loaded with doxorubicin and 
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demonstrated superior delivery to HeLa cells when compared to free doxorubicin.80 A 
list of CNT-based tumor-targeted drug delivery systems (DDS) is given in Table 1. 
CNTs as carriers of immunoactive compounds, proteins, and genetic materials 
Gene therapy aims to use genetic material to treat diseased cells by repairing the 
cause of the disease. Since genetic materials are not able to cross the biological 
membranes, the use of viral or nonviral vectors to carry the gene and internalize it 
into the cell is necessary. Nonviral vectors are less efficient than viral vectors81 and 
short lived, 82 but they are far safer.83, 84 Pantarotto and coworkers developed novel 
functionalized SWCNT-DNA complex and reported high DNA expression compared 
with naked DNA.85  
 
Figure 7.  Preparation of SWNTs-DOX after inclusion of bioadhesive 
polymers to enhance nanotubes dispersability in aqueous phase. 58 
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Table 1. CNT-based tumor- targeted drug delivery systems (DDS) 
Functionalized SWCNTs have been used as suitable non-viral carriers of 
macromolecules and internalization of such macromolecules into living cells by 
CNTs has been reported to take place via energy-dependent endocytosis.86 Confocal 
microscopy and flow cytometry results have shown much greater fluorescent activity 
of protein and DNA when conjugated to SWNTs as compared to the naked 
macromolecules indicating that CNTs are promising vectors for gene and protein.87 
Cai and coworkers introduced an approach to gene delivery named as “carbon 
nanotube spearing”.88 Plasmid DNA with a fluorescent protein were immobilized onto 
nickel-embedded CNTs and was “speared” into Bal 17 B lymphoma cells using a 
magnetic field, which produced high transfection in the target cells.88 In another 
study, HeLa cells were exposed to DNA attached SWCNTs at 37°C which resulted in 
gene internalization. However, at lower temperature (e.g., 4°C), no internalization 
took place, possibly because gene transport occurs by energy-dependent 
endocytosis.87  
Gene silencing, a recent strategy in gene therapy, involves the use of small interfering 
RNA (siRNA) in the treatment of many diseases, including various cancers. In cancer, 
antitumor immunity might be inhibited by suppression of cytokine signaling 1 
(SOCS1). siRNA can be conjugated to phospholipid-functionalized SWCNTs using a 
cleavable disulfide linker, resulting in efficient gene silencing and subsequent death 
Reference  CNTs  Drug  Tumor-targeted modules  Tumor 
Chen et al. [74]  SWNTs  Taxoid  Biotin and a spaces  Leukemia 
Heister et al. [149]  SWNTs  Doxorubicin  A monoclonal antibody  Colon cancer 
Bhirde et al. [150]  SWNTs  Cisplatin  Epidermal growth factor  Squamous carcinoma 
Dhar et al. [67]  SWNTs  Cisplatin  Folate  
Nasopharyngeal epidermoid 
carcinoma etc. 
Liu et al. [73]  SWNTs  Doxorubicin  Rgd  
Breast cancer, 
Glioblastoma 
Zhang et al. [58]  SWNTs  Doxorubicin  Folate  Cervical carcinoma 
Mc Devitt et al. [151]  SWNTs  Radionuclide  Thiolated-antibody  Burkitt lymphoma 
Liu et al. [72]  SWNTs  Paclitaxel  –  Breast cancer 
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of the targeted cell.89 In another study, amino-functionalized MWNTs-siRNA 
complexes have shown successful suppression of tumor and prolonged survival in 
lung tumor of an animal model.90 Functionalized SWCNTs have been designed as 
carrier for siRNA for internalization into K562 cells and subsequent inhibition in the 
production of cyclinA(2) and treatment of chronic myelogenous leukemia. Many 
types of cancer (e.g., leukemia) can overexpress cyclinA(2), and suppression of this 
material using siRNA-CNTs can promote apoptosis in the targeted tumor.91 In another 
finding, functionalized SWNTs have been conjugated to telomerase reverse 
transcriptase (TERT) siRNA which successfully silenced the target gene, and tumor 
growth was inhibited in vitro using murine tumor cell lines and in vivo using a mouse 
model.92 Similarly in another study CNTs cationically functionalized with 
polyethylene imines have been shown capable of complexing with siRNA and 
generating a silencing activity of up to 30% and cytotoxicity of up to 60%.93 
Streptavidin is a protein that has anticancer activity.94  However, due to its very large 
molecular weight, it does not penetrate the cells. Kam et al.95 used a conjugate of 
streptavidin with SWCNT-biotin, which resulted in internalization of the protein into 
model cancer cells by adsorption-mediated endocytosis. Transmission electron and 
confocal microscopy have shown that MWCNTs can act as transporters of the 
recombinant ricin A chain protein, resulting in high death rates of cancer cells.96 
Immunotherapy may be an alternative to gene therapy in cancer treatment. Antitumor 
immunotherapy using CNTs has gained interest among researchers. Tumor-specific 
monoclonal antibodies, radiometal ion chelates, and fluorescent probe have been 
conjugated to SWCNTs and successful targeting to tumor has been reported.97 The 
antitumor immune response was increased when MWCNTs were conjugated to tumor 
lysate protein as an antigen.98 
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Glioma is a brain tumor that is able to evade the host immune system.99, 100 
Macrophages have a preferential affinity towards CNTs when compared to glioma 
cells.101 Van Handel and coworkers102 developed an immunotherapy approach using 
MWNTs against GL261 murine intracranial glioma cancer model, based on the fact 
that macrophages prefer to engulf CNTs compared with glioma cells. An increase in 
the influx of macrophages into the glioma cells with MWNTs was reported. Also, an 
increase in the levels of IL-10 expression was observed, suggesting that 
immunomodulation using CNTs is a possible strategy to treat cancer. 
Reduction in the tumor volume and prolonged survival in animal models was reported 
when angiogenesis targeting antibodies E4G10 were attached to SWNTs via 
radiometal ion chelates.103 Oxidized MWCNTs has been reported to retard tumor 
growth when injected subcutaneously to a hepatocarcinoma bearing animal to induce 
an immune response.104 This suggests that CNTs themselves could possibly be 
surface-engineered to have anticancer activity by inducing an immune response 
against tumor. 
A major hurdle to effective anticancer therapy is the multidrug resistance caused by 
enhanced efflux of anticancer drugs by the overexpressed p-glycoprotein, resulting in 
poor anticancer effect.75, 76 Li et al. reported that SWCNTs functionalized with p-
glycoprotein antibodies and loaded with the anticancer drug doxorubicin 
demonstrated higher cytotoxicity against K562R leukemia cells compared with free 
doxorubicin.105 
CNT mediated photothermal therapy of cancer 
CNTs are also welcomed in the field of thermal therapy and considered to be a non-
invasive, harmless and highly efficient technique.106 CNTs are able to absorb light in 
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the near infrared (NIR) region, resulting in heating of the nanotubes. This unique 
property of CNTs has been exploited as a method to kill cancer cells via thermal 
effects.86, 107-119 According to Gannon et al.107 The incubation of the nanotubes 
functionalized using kentera (a polyphenylene ethynylene-based polymer) were 
studied using hepatic tumor cells followed by application of radiofrequency field, 
which demonstrated a concentration-dependent thermal destruction and complete 
necrosis of the tumor cells. By contrast, tumor cells that were injected with the 
Kentera alone (without CNTs) were viable after the application of the radiofrequency 
field. Both in vitro and in vivo tests have shown thermal destruction of cancer cells in 
the presence of SWNTs with exposure to radiofrequency. A formulation based on FA-
PL-PEG functionalized SWCNTs was used for targeting cancer cells, which over-
express folate receptors.109 Selective cancer cell destruction was achieved by 
continuous NIR radiation of SWCNTs. The NIR triggered cell death has been shown 
to remain nontoxic for neighboring normal cells. 86 This research presented a novel 
application of CNTs in cancer therapy. Another study utilizing the NIR characteristic 
of CNTs involved the destruction of breast cancer cells by non-covalently attaching 
monoclonal antibodies against membrane markers: insulin like growth factor 1 
receptor (IGF1R) and human endothelial receptor 2 (HER2). The antibodies were 
attached using π-π interactions of pyrene rings onto the sidewalls of SWCNTs.120 
CNTs mediated photodynamic therapy (PDT) 
PDT could potentially be an ideal cancer treatment therapy capable of efficiently 
destroying tumors while at the same time sensitizing the immune system to seek out 
and destroy metastases.121 Singlet oxygen is one of the most important agents 
generated during PDT, which can react rapidly with cellular molecules and mediate 
cellular toxicity to cause cell damage, ultimately leading to cell death. However the 
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lifetime and diffusion distance of singlet oxygen are very limited. Zhu et al.122 
synthesized a novel molecular complex photosensitizer, an ssDNA aptamer, and 
SWCNTs, which were able to control and regulate singlet oxygen generation, 
whereby more efficient, reliable and selective PDT could be guaranteed. 
CNTs for other therapeutic applications 
The use of CNTs in therapeutic applications other than cancer is also developing. 
Surface-engineered CNTs may be able to capture pathogenic bacteria in liquid 
medium.123-125 Thus, CNTs themselves might have antimicrobial activity since 
microorganisms may be adsorbed onto the surfaces of CNTs. It has been reported that 
the electronic properties of SWNTs may regulate the antibacterial activity in E. coli. 
The antibacterial effect was attributed to CNT induced oxidation of the intracellular 
antioxidant glutathione, resulting in increased oxidative stress on the bacterial cells 
and eventual death.126 Functionalized CNTs can attach covalently to amphotericin B 
and transport it into mammalian cells, thus demonstrating their ability to act as 
carriers for antimicrobial agents.127, 128  
In vitro and in vivo toxicity of CNTs 
Although there are exciting prospects for the application of CNTs in medicine, 
concerns over adverse and unanticipated effects on human health have also been 
raised. So far, many studies have been performed to evaluate the toxicological effects 
of CNTs both in vitro and in vivo.11 The CNT cytotoxicity was attributed to 
variability in the doses, physical form like length and type of CNTs, 129 effect of metal 
catalyst impurities, 130 degrees of functionalization and dispersion of CNTs.131 Metal 
catalysts are the main source of cytotoxicity in CNTs.132, 133 Iron, the most common 
catalyst for growing CNTs, may boost the free radical reactions in the living cells.134 
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Becker et al.135 proved that CNTs shorter than 189 +/- 17 nm have greater 
cytotoxicity. Furthermore, CNTs are required to be hydrophilic as drug carriers. 
Therefore, the surface chemistry plays an important role in improving the 
biocompatibility of CNTs. Few reports have demonstrated significant reduction in the 
cytotoxicity of CNTs due to the high degree of functionalization on CNT side 
walls.130, 136, 137 Functionalized SWCNTs (f-SWCNTs) are much less toxic than 
surfactant-stabilized SWCNTs.138 In a typical experiment, immunoregulatory cells 
(macrophages, B and T lymphocytes) were incubated in two types of amino group f-
SWCNTs, one being highly soluble and another forming stable suspension in aqueous 
solution. The activities of the immunoregulatory cells are not influenced by the highly 
soluble CNTs, whereas proinflammatory cytokines are secreted by macrophages in 
the CNT suspension.139 Another group studied the influence of SWCNTs with 
different degrees of agglomeration on primary cultures derived from chicken 
embryonic spinal cord (SPC) or dorsal foot ganglia (DRG). 140 Significant decrease in 
DNA content was more pronounced when cells were exposed to highly agglomerated 
SWCNTs as compared with better-dispersed SWNT bundles. 
 Bottini et al.141 compared the toxicity of pristine and oxidized MWCNTs on human T 
cells and found that the MWCNTs were more toxic and induced massive loss of cell 
viability through programmed cell death.  
Pulskamp et al.133 did not observe any acute toxicity on cell viability upon incubation 
with all CNT products. However, an increase in reactive oxygen species was observed 
due to the presence of metal particles as well as metalloids in commercial nanotubes, 
while treatment with a highly ultra-purified form of CNTs had no biological adverse 
effects. 
Yang et al.142 reported long-term accumulation and low toxicity of SWNTs in 
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intravenously exposed mice. No acute toxicity was reported by Zeni et al.143 on 
administration of SWCNTs. Similarly, other reports show low or no cytotoxic effects 
due to exposure to CNTs. Huezko and Lange reported null risk of skin irritation and 
allergy on dermatological trials of CNTs. 
Functionalized SWCNTs have been used as drug carriers with paclitaxel.143, 144 
Paclitaxel, being insoluble in water, is currently clinically administered as a highly 
toxic formulation with Cremophor EL. However, using SWNTs as a carrier allowed 
for a prolonged circulation of the drug and a 10-fold higher uptake by tumor cells.144 
The high uptake of SWNT complexes by the reticuloendothelial system may endanger 
liver and spleen as they may suffer toxic effects from SWCNT deposition and 
accumulation. One of the main problems faced with intravenous administration is the 
rapid clearance through blood, and another is the toxic effect to other organs and 
tissues.145 Another study tested the toxicity of intravenously administered 
functionalized SWCNTs in mice and demonstrated no evidence of toxicity. PEG-
SWCNTs were observed to be gradually removed from the body following an 
intravenous administration in mouse models with no evidence of toxicity during the 
excretory process.146 
Zhuang et al. used PEGylated SWNTs conjugated to RGD peptide that specifically 
binds to integrin αvβ3, expressed on the surface of numerous tumor cells. This 
formulation was intravenously injected into U87MG tumor bearing mice. The RGD –
bound SWCNTs showed a higher tumor uptake as compared to SWCNTs alone.147 
Conclusion 
Nano delivery systems hold great potential to overcome many of the present obstacles 
of drug delivery, of which carbon nanotubes have been proposed and actively 
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explored as multipurpose innovative carriers for drug delivery and diagnostic 
applications. They have many unique physical, mechanical and electronic properties, 
and these distinct and exceptional properties have made it possible to exploit CNTs as 
drug delivery systems for biomedical applications. CNTs are promising carriers of 
both small drug molecules as well as macromolecules such as genes and proteins. 
Functionalization of CNTs with an organic moiety has made possible their use in 
diagnostics for imaging as well as for targeting purposes, especially in cancer therapy. 
Nanotube drug delivery holds future promise for high treatment efficacy combined 
with minimal side effects for cancer therapy with low drug doses. 
Even though CNTs are playing a larger and most promising role in the field of 
nanomedicine, more research is required to guarantee safety in drug delivery. 
Functionalized CNTs have been considered biocompatible and safe for drug and 
biomolecular delivery applications, as they are soluble in physiological media and 
nontoxic. They have shown no accumulation in the tissues and can be readily excreted 
through the renal route. Toxicity studies are critical to establish the full in vivo 
potential of CNTs for drug delivery before their actual application and marketing and 
in order to understand the toxic impact of the systemic delivery of carbon nanotubes 
in greater detail, more extensive toxicity, safety and efficacy studies on animal 
models and in humans over a longer time frame need to be performed. The effects of 
CNTs aggregation, size, length, functionalization, metal impurities and polymers 
safety require more thorough research. Functionalization of SWCNTs and its effects 
on aggregation and consequent genotoxicity also needs to be evaluated. Overall, the 
use of CNTs for delivery of drugs and biomolecules is a significant development in 
the field of therapeutic nanomedicine. 
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Chapter 2 
Instrumentation 
Abstract 
An understanding of the structure, surface morphology and elemental 
composition of the nanoparticles is essential to know the specific properties of 
the nano-materials under study. This chapter describes the principles of different 
instruments, which were employed for various characterizations of nanoparticles 
(NPs) and also analytical instruments used in biological studies. Various 
microscopic techniques, spectroscopic methods and other characterization 
techniques are being discussed in this chapter. In addition, the application of 
nanoparticles in vitro is also visualized with the help of various microscopic 
techniques. The techniques used for the characterization studies and nanoparticle 
applications are explained in this chapter. 
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Introduction 
Proper characterization of nanomaterials is highly essential for their accurate 
analysis. Microscopic techniques and spectroscopic techniques are the  
common characterization methods for the characterization of various 
nanoparticles (NPs). Microscopic techniques including both optical and 
electron microscopes were used in our research. For studying the 
internal structure and surface morphology of nanoscale materials 
electron microscopic techniques are inevitable. NPs were characterized 
for their morphology using Transmission Electron Microscope (TEM), Scanning 
Electron Microscope (SEM) and Atomic Force Microscope (AFM). The 
elemental composition studies of the nano samples were carried out 
using X-ray Photoelectron Spectroscopy (XPS or ESCA), and UV-visible 
spectrophotometer (UV-Vis spectroscopy) was used to study the electronic 
excitations. Zetasizer has been used for measuring the zeta potential of the 
samples. We are discussing in detail about the general working principle 
and sample preparation of various electron microscopic methods, optical 
microscopic methods, spectroscopic techniques and other characterization 
techniques employed to analyze the NPs. 
 
Microscopic techniques 
Transmission Electron Microscope (TEM) 
Transmission Electron Microscope (TEM) is a scientific microscopy 
technique, which utilizes a beam of electrons instead of light to analyze the 
ultra-thin specimens at a significantly higher resolution. This enables the 
examination of samples even a small single column of atoms can be 
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observed clearly, which is in the order of few angstroms. TEM analysis 
provides information regarding the morphology like size, shape and 
arrangement along with crystallographic and compositional nature of particles at 
the nanometer scale. 
Working principle 
TEM is composed of an electron emission source for the generation of 
electron stream, a vacuum system in which the electrons travel, a series of 
electromagnetic lenses to guide the beam of electrons and electrostatic 
plates to manipulate the beam. Imaging devices, which can create an image 
from the electrons that exit the system, are also required. Electrons are usually 
generated by thermionie emission from a tungsten filament or alternatively by 
field electron emission under high vacuum. The electrons are then 
accelerated by an electric potential which allow them to travel through the 
vacuum in the column of microscope and are focused by electrostatic and 
electromagnetic lenses on to the sample, thus allowing the electron beam 
to travel through the specimen. Depending on the density of materials present, 
some of the electrons are scattered and disappear from the beam. The 
transmitted beam contains information about electron density, phase and 
periodicity. The unscattered electrons hit a fluorescent screen below the 
specimen, which gives a shadow image of the specimen with its different 
parts displayed in varied darkness according to their density. This image 
is then magnified and focused by an imaging device and is detected by a 
sensor or charge-coupled device (CCD) camera. The TEM used in our studies is 
JEOL JEM-2200-FS Field Emission Transmission Electron Microscope 
operating at an accelerating voltage of 200 kV. 
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Sample preparation 
Samples were prepared on a 200 mesh copper (Cu) grid with carbon film 
coating. The solid sample for TEM observation was prepared by depositing 
the powder onto the grid with carbon coating surface. For the preparation of 
liquid samples, the grids were initially subjected to hydrophilic treatment using 
JEOL Datum HDT- 400 hydrophilic treatment device for 30 seconds. A drop 
of the sample was then added directly onto the supporting grid and was 
allowed to air dry at room temperature for further analysis. The grid 
with the sample was then screwed onto the sample holder and introduced 
into the sample chamber of the instrument. 
Scanning Electron Microscope (SEM) 
Scanning Electron Microscope (SEM) images the surface of sample using 
focused beam of high energy electrons in a raster scan pattern to generate a 
variety of signals at the surface of samples. The signals that are derived 
from the electron-sample interactions reveal information regarding 
the surface morphology, chemical composition, crystalline structure and 
orientation of materials. SEM has a large depth of field which allows a 
large amount of the sample to be in focus at one time and produces a two-
dimensional image which is a good representation of the three dimensional 
sample. It also has a magnification range from 15 X to 200,000 X and a 
resolution of 5 nm. The advantage of SEM analysis is the non-destructive 
nature, which does not lead to volume loss of the sample, and the same 
material can be analyzed repeatedly. 
Working principle 
In a typical SEM, an electron beam is therminionically emitted from an electron 
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gun fitted with cathode. The electron beam, which typically has an energy ranging 
from 0.5-40 kV, is focused by one or two condenser lenses to a spot about 04 nm 
to 5 nm in diameter. Accelerated electrons of high kinetic energy produce a 
variety of signals by energy dissipation when they hit the sample. These signals 
include secondary electrons, back-scattered electrons (BSE), diffracted 
back-scattered electrons (DBSE), photons, visible light and heat, each of which 
can be detected by specialized detectors. Secondary electrons along with BSE are 
commonly utilized to produce images of the samples, whereas secondary electrons 
are most valuable for depicting morphology and topography of samples, while 
BSE being valuable for illustrating the contrast in composition. DBSE are used to 
determine crystal structure and orientations of minerals, whereas photons, which 
have the characteristics of X-rays are used for elemental analysis. Electronic 
amplifiers of various types are used to amplify the signals, which are displayed 
as variations in brightness on a cathode ray tube (CRT). The raster scanning 
of CRT display is synchronized with that of the beam on the specimen within 
the microscope and the resulting image is therefore a distribution map of the 
intensity of the signal being emitted from the scanned area of the specimen. The 
image may be captured by photography from a high-resolution cathode ray tube. 
However, the images are digitally captured, displayed on a computer monitor and 
saved to the computer's hard disk in the modern machines. 
For our SEM studies, we used JEOL JSM-7400F Field Emission Scanning 
Electron Microscope operating at 5 kV accelerating voltage. 
Sample preparation 
Solid samples for SEM imaging can be mounted easily and rigidly on a specimen 
holder using a small piece of double-sided carbon tape or silicon substrate. To 
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make specimen electrically conducting and electrically grounded, the sample on 
stubs was coated with platinum (approximately 511 rim thickness) using Hitachi 
E-1030 ion sputter machine before microscopic examination. This coating helps 
to prevent the accumulation of static electric charges that occur when the electron 
beam interacts with the sample during the analysis. For liquid samples a small 
piece of silicon substrate or mica substrate was mounted on the specimen stub and 
the sample was dropped over that and allowed to air dry or vacuum dry depending 
on the solvent used. 
Atomic Force Microscope (AFM) 
Atomic Force Microscopy (AFM) is a very high-resolution scanning probe 
microscopy with resolution in the order of fractions of a nanometer. The AFM can 
be operated in a number of modes depending on the application In general, 
possible imaging modes are divided into static (also called contact) modes and a 
variety of dynamic (non-contact or "tapping") modes where the cantilever is 
vibrated. 
Working Principle 
The AFM consists of a cantilever with a sharp tip (probe) at its end that is used to 
scan the specimen surface. The cantilever is typically silicon or silicon nitride 
with a tip radius of curvature in the order of nanometers. When the tip is brought 
into the proximity of a sample surface, forces between the tip and the sample 
lead to a deflection of the cantilever according to Hooke's law. Typically, the 
deflection is measured using a laser spot reflected from the top surface of the 
cantilever into an array of photodiodes. Other methods that are used include 
optical interferometry, capacitive sensing or piezoresistive AFM cantilevers. 
These cantilevers are fabricated with piezioresistive elements that act as a strain 
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gauge. Using a wheatstone bridge, strain in the AFM cantilever due to deflection can 
be measured, but this method is not as sensitive as laser deflection or 
interferometry. If the tip was scanned at a constant height, there is a risk of the tip 
colliding with the surface, causing damage. Hence, in most cases, a feedback 
mechanism is employed to adjust the tip-to-sample distance to maintain a constant 
force between the tip and the sample. Traditionally, the sample is mounted on a 
piezoelectric tube, which can move the sample in the z direction for maintaining a 
constant force and the x and y directions for scanning the sample. Alternatively a 
'tripod' configuration of three piezo crystals may be employed with each 
responsible for scanning in the x, y and z directions. This eliminates some of the 
distortion effects seen in a tube scanner observed in newer designs. The tip is 
mounted on a vertical piezo scanner while the sample is being scanned in X and V 
using another piezo block. The resulting map of the area z = f (x.v) represents the 
topography of the sample. 
The AFM used in our studies is Asylum Research, 
Sample preparation 
The samples for AFM analysis was spin coated onto a Si substrate or glass slide. 
 Confocal Laser Scanning Microscope (CLSM) 
Confocal microscopy is an optical imaging technique used to increase the optical 
resolution and contrast of a micrograph by using point illumination, and a spatial 
pinhole to eliminate out of focus light in the specimens that are thicker than the 
focal plane. This microscopy enables the reconstruction of three-dimensional 
structures from the obtained image. 
Working principle 
Marvin Minsky patented the principle of confocal imaging in 1957. A 
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confocal microscope uses point illumination and a pinhole in an optically 
conjugate plane in front of the detector to illuminate out of focus signal-the name 
"confocal" stems from this configuration principle. This is better than that of the 
wide-field microscopes because only light produced by fluorescence very close to 
the focal plane can be detected yielding to the improved optical resolution of the 
image. However increased resolution is obtained at the cost of decreased signal 
intensity, making long exposures a requirement. 
CLSM use a pair of mirrors, one at x and other at y-axis to scan the laser across 
the samples and descan the image across a fixed pinhole and detector. CLSM can 
have a programmable sampling density and very high resolution. The thin optical 
sectioning of CLSM makes it possible to obtain 3D imaging and surface profiling of 
the samples. Cutting edge developments of CLSM now allows better than video 
rate imaging by multiple micro electro-mechanical systems based scanning 
mirrors. The laser light source has the additional benefits of being available in a 
wide range of wavelengths. 
 Sample preparation 
CLSM images of the biological samples (cell lines) were obtained by 
growing specific cell lines on a glass-bottom dish. The bright field image is 
obtained under a normal light source whereas the fluorescent image can be 
obtained based on the excitation and emission wavelength of the nanoparticles or 
dyes used in the study. In the case of blue fluorescent NPs and DAPI (dye 
staining the nucleus of the cells), we have utilized excitation wavelength of 405 
nm (blue filter). In the case of green fluorescent materials, Tubulin Marker 
(dye staining the micro spindles of the cells) and Lysotracker (dye staining 
the lysosomes of the cells) at excitation of 488 nm is used and for red fluorescent 
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materials Nile Red dye, 561 nm was used as the excitation wavelength. To study 
the fluorescence of nanoparticles, they were added onto the cover slips and 
subjected for analysis. 
In our studies we have used Olympus IX81 confocal laser scanning microscope. 
Phase Contrast Microscope 
Phase contrast microscopy is a type of light microscopy, which enhances the 
contrast of transparent and colorless objects by influencing the optical path of 
light. It employs an optical mechanism to translate minute variations in phase into 
corresponding changes in amplitude, which can be visualized as differences in 
image contrast, and no staining is required to view the samples. Most of the details 
of living cells is undetectable in bright field microscopy, due to lack of 
contrast between the structures with similar transparency and because of 
the lack of natural pigmentation in the sample under study. Phase contrast 
microscopy distinguishes wide variation in refractive index shown by various 
biological organelles thus yielding an image with better resolution. 
Working principle 
Only two specialized accessories are required to convert a bright field microscope 
for phase contrast observation; a specially designed annular diaphragm which is 
constructed as an opaque flat-black (light absorbing) plate with a transparent 
annular ring, is positioned in the front focal plane of the condenser so that the 
specimen can be illuminated by defocused, parallel light wave fronts 
emanating from the ring, and a phase plate which is mounted in or near the 
objective rear focal plane in order to selectively alter the phase and amplitude of 
the surrounding light passing through the specimen. Phase contrast technique 
allows phase of the light passing through the object under study to be 
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inferred from the intensity of the image produced by the microscope. 
For our studies we had used Nikon Eclipse TE2000-U Microscope. 
Sample preparation 
For phase contrast analysis of biological samples, cells were grown in 
standard T25 flask or on 6 well plates. 
 
Spectroscopic techniques 
UV-Vis Spectroscopy 
Ultraviolet-Visible spectroscopy is the optical spectroscopy that investigates the 
absorption of light in the visible, ultraviolet and near infrared ranges by 
molecules that are in a gas or vapor state or dissolved molecules/ions. It is ideal 
for characterizing the optical and electronic properties of various materials 
such as, powders, monolithic solids, and liquids. 
Working principle 
Measurements in the UV-Visible region cover wavelengths from about 200 
nm to 800 nm. When the light passes through the sample, some of the light 
energy is absorbed by the sample. The absorption of ultraviolet or visible 
radiation by a molecule leads to the transitions among the electronic energy 
levels of the molecule. The optical spectrometer records the wavelength at which 
absorption occurs. A graph of absorbance against wavelength gives the samples 
absorption spectrum. It compares the intensity of light before and after passing 
through the sample and ratio of the intensities is called transmittance. The 
wavelength at the maximum absorption will give information about the structure 
of the molecule present in the sample, and the extent of the absorption is 
proportional to the amount of species absorbing the light. 
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The UV-Vis spectrophotometer used in our works is Shimadzu 
UV4100PC/3100PC UV visible spectrophotometer. 
Sample preparation 
The sample to be measured was dispersed well in a suitable solvent. The chosen 
solvent alone was taken as the reference agent in one quartz cuvette and the 
sample solution was taken in another quartz cuvette and kept in the chamber for 
the measurement. 
X-ray Photoelectron Spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) is also known as Electron Spectroscopy 
for Chemical Analysis (ESCA). It is a quantitative spectroscopic technique that 
measures the elemental composition, empirical formula, chemical state and 
electronic state of the elements that exists within the material. This instrument 
measures the relative composition of elements present in the surface of the 
samples. 
Working principle 
This spectroscopic technique uses mono-energetic soft X-rays to eject electrons from 
the inner shell orbitals of atoms. When the X-ray beam hits the sample surface, 
the energy of X-ray photons is absorbed by the core electrons and results in 
ionization and emission of photoelectrons from the sample surface with specific 
kinetic energies. The kinetic energy distribution of the emitted photoelectrons 
can be measured using any appropriate electron energy analyzer and a 
photoelectron spectrum can thus be obtained. The photo-ionization and analysis 
of the kinetic energy distribution of the emitted photoelectrons is utilized to study 
the composition and electronic state or the surface region of a sample. The energy 
of photo emitted core electron is a function of its binding energy and is the 
	   47	  
characteristics of the element from which it is emitted. When the core electron is 
emitted from the atom by incident X-rays, the hole is filled by the electron from 
the outermost orbital. At the same time a second electron gets emitted and is called 
as auger electron. This auger electron emission occurs within 10-14 s after the emission 
of photoelectrons leading to emission of two types of electrons. The detector 
detects the kinetic energy of all the collected electrons contributed from both 
photoelectrons and auger electrons. This spectrum from a mixture of elements 
is approximately the sum of peaks of the individual elements present. The 
quantitative data obtained from the peak heights or areas and the identification of 
chemical state can be made from exact analysis of peak positions and separations. 
XPS detects all elements with an atomic number (Z) of 3 and above. It cannot 
detect hydrogen (Z = 1) or helium (Z = 2) because the diameter of these orbitals 
is so small, reducing the catch probability to almost zero. 
For experimental studies, we used Kratos Analytical X-ray 
Photoelectron Spectroscopy IX PSI with monochromatic Al, Ka X-ray 
source with photon energy of 1487.6 eV. The instrument was operated at 12 
kV and 15 mA under high vacuum condition with vacuum pressure 
maintained below 10-9  Torr. 
Sample preparation 
Powder samples were added onto the double-sided carbon film or white film 
fixed on to the XPS specimen holder. For liquid samples, a drop of the 
sample solution was dropped on a small piece of silicon substrate and the 
sample was allowed to vacuum dry or air dry. The silicon substrate with the 
dried sample was then mounted on the double-sided tape fixed on the 
specimen holder. 
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Other instrumentation techniques  
Zetasizer 
Zetasizer is commonly used to measure the size, poly dispersity and zeta 
potential of the NPs to optimize the production processes. The development of a 
net charge at the particle surface affects the distribution of ions in the 
surrounding interfacial region, resulting in an increased concentration of 
counter ions (ions of opposite charge to that of the particle) close to the surface. 
Thus, an electrical double layer exists around each particle. The liquid layer 
surrounding the particle exists as two parts; an inner region, called the Stern layer, 
where the ions are strongly bound and an outer, diffuse region where they are less 
firmly attached. Within the diffuse layer there is a notional boundary inside 
which the ions and particles form a stable entity. When a particle move (e.g. due 
to gravity), ions within the boundary move with it, but any ions beyond the 
boundary do not travel with the particle. This boundary is called the surface of 
hydrodynamic shear or slipping plane. The potential that exists at this boundary 
is known as the Zeta potential. 
Working principle 
When an electric field is applied across an electrolyte, charged particles suspended 
in the electrolyte are attracted towards the electrode of opposite charge, whereas 
viscous force acting on the particles tends to oppose this movement. When the two 
opposing forces reach equilibrium then the particles move with a constant 
velocity. The velocity of a particle in an electric field is called the electrophoretic 
mobility and this knowledge can help us to obtain the zeta potential of the 
particles. Zeta potential is a consequence of the existing surface charge of the 
sample, and can also give information on electrical interaction between the 
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dispersed particles. It is possible to assess the stability of suspensions and 
emulsions by means of zeta potential. For our research work, we used Malvern 
Zetasizer Nano-ZS. 
Sample preparation 
The diluted colloidal solution of NPs was taken in a cuvette and the dip electrode 
was fitted immersed in the colloidal solution. The cuvette was fitted into the 
holder and kept undisturbed for 120 s to neutralize the movement of NPs in 
colloidal solution and the measurement was carried out at 25°C. 
Particle size analyzer 
Dynamic light scattering (DLS) technique was utilized to analyze the 
size and the distribution profile of particles suspended in the solution. It is 
a non-invasive well-established technique for measuring the size of 
molecules and particles in the submicron region. 
Working principle 
Particles, emulsions and molecules in suspension undergo Brownian 
motion. This is the motion induced by the bombardment of solvent 
molecules that are moving by themselves due to their thermal energy. If 
the particles or molecules are illuminated with a laser, the intensity of the 
scattered light fluctuates at a rate that is dependent upon the size of the 
panicles, as smaller particles are "kicked" further by the solvent molecules 
and move more rapidly. Analysis of these intensity fluctuations yields the 
velocity of the Brownian motion and hence the particle size can be assessed 
using the Stokes-Einstein relationship. The diameter that is measured in 
DLS is called the hydrodynamic diameter and refers to how a particle 
diffuses within a fluid. The diameter obtained by this technique is that of a 
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sphere that has the same translational diffusion coefficient as the particle 
being measured. The translational diffusion coefficient will depend not only 
on the size of the particle “core”, but also on the surface structure, as well as the 
concentration and type of ions in the medium. This means that the size can 
be larger than measured by the electron microscopy, where the particle is 
removed from its native environment. In most instruments monochromatic 
coherent He-Ne laser with a fixed wavelength of 633 nm is used as the light 
source. Light scattered by the particles is detected with only one detector, which is 
placed at 90° to the incident laser beam. For our research works, we used Malvern 
Zetasizer Nano-ZS. 
Sample preparation 
The diluted colloidal solution of NPs was taken in cuvette and the cuvette was 
fitted into the holder and kept undisturbed for 120 s to neutralize the movement of 
NPs colloidal solution and the measurement was carried out at 25°C. The resultant 
profile yields a graphical representation of the size distribution of NPs.  
Conclusion 
Characterization instruments can easily determine the various properties of the 
nanomaterials. As the area of research in nanoscience and nanotechnology is 
expanding rapidly, a need for evolutionary approaches in the field of 
instrumentation is also required. The instrumentations used in our research are 
detailed out in this chapter.  
 
 
 
 
	   51	  
Chapter 3 
Targeted drug delivery using PEG biofunctionalized folate 
conjugated SWCNTs against breast cancer cells 
 
Abstract 
 Medical science and biomedical engineering has advanced to a significant extent, but 
the therapeutic development of anti-cancer strategies is still limited. In this work, we 
have developed a targeted drug delivery system (DDS) based on SWCNTs 
biofunctionalized with polyethylene glycol (PEG), conjugated with folic acid (FA) as 
targeting moiety and loaded with anticancer drug doxorubicin (DOX) for selective 
killing of tumor cells. The prepared nanotubes were characterized for their 
morphological features and their elemental composition. In vitro drug release studies 
showed that the drug (DOX) binds at physiological pH (pH 7.4) and is released at a 
lower pH (lysosomal pH 4.0), which is the characteristic pH of the tumor 
environment. A sustained release of DOX from the SWCNTs was observed for a 
period of three days, which effectively caused the death of the breast cancer cells. The 
nanotubes were incubated with breast cancer cells and their biocompatibility and anti-
proliferative effects were analyzed. We found that the targeted nanotubes were non-
toxic to normal cells while toxic to tumor cells. Cellular uptake of the targeted 
nanotubes was studied in vitro using confocal microscopy. Time dependent drug 
effect was also studied using normal cells and tumor cells. Our results show 
significant internalization and retention of the nanotubes inside the tumor cells, 
inducing apoptosis, thus indicating that this study with folate conjugated and DOX 
loaded nanotubes can be a promising targeted drug delivery vehicle for cancer 
therapy. 
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Introduction 
The emerging field of nanobiotechnology bridges the physical sciences with 
biological sciences via chemical methods by developing novel tools and platforms for 
understanding biological systems and in disease diagnosis and treatment.1-3 Targeted 
drug delivery is a very potential and desired requirement in cancer nanotherapeutics.4 
Many nanodrug carriers with controlled drug release have already been developed.5-8 
Among the currently available delivery vehicles such as liposomes, 9 polymeric 
nanoparticles 10, 11 and inorganic nanoparticles,12 single walled carbon nanotubes 
(SWCNTs) are emerging as one of the most promising delivery vehicles for cancer 
diagnosis and chemotherapy. SWCNTs, which comprise of thin sheets of benzene 
rings rolled up into seamless cylinders, have attracted significant attention for use in 
biomedical applications due to their significant advantages including good cell 
membrane permeability, high drug loading capacity, pH dependent therapeutic 
unloading and prolonged circulation time.13-21 SWCNT-based drug delivery systems 
have been designed and prepared, and it has been proved by many in vitro results that 
these multifunctional SWCNTs could greatly improve the therapeutic efficiency of 
the drug while reducing their toxicity.22-25 
Unmodified SWCNTs have highly hydrophobic surfaces and are not soluble in 
aqueous solutions. For biomedical applications, functionalization is required to 
solubilize SWCNTs and to render biocompatibility and low toxicity. Surface 
functionalization of SWCNTs can be made by covalent or non-covalent chemical 
reactions. Oxidation is one of the most common methods to covalently functionalize 
SWCNTs, 26 where the CNTS are treated with oxidizing agents like nitric acid. Non-
covalent functionalization of SWCNTs can be carried out by coating with amphiphilic 
surfactant molecules or polymers.27 Since SWCNTs are insoluble in water, they 
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aggregate in the presence of salts, and thus cannot be directly used for biological 
applications due to the high salt content of most of the biological solutions. Further 
modification can be achieved by attaching hydrophilic polymers such as poly 
(ethylene glycol) (PEG) to oxidized SWCNTs, yielding SWCNT-polymer conjugates 
stable in biological environments.28, 29 
PEGylation is a good strategy to impart various functionalities, high water solubility, 
biocompatibility and prolonged blood circulation half-lives. PEG is composed of 
repeating ethylene glycol units -(CH2-CH2-O)n-, where the integer n is the degree of 
polymerization. PEG-coated SWCNTs are obtained by adsorption of amphiphilic 
polymer functionalized with activated PEG chains onto SWCNTs.30 Polymers bind to 
SWCNTs through hydrophobic interactions between the lipophilic moieties and the 
graphitic SWCNT sidewalls, leaving the PEG chains and other hydrophilic groups 
projecting from the sidewall, thus imparting water solubility and biocompatibility.31 
PEGylation also reduces non-specific uptake by cells within the recticuloendothelial 
system, thereby increasing the circulation in blood. 
In this work, harnessing the advantages of PEGylated SWCNTs, we have developed a 
SWCNT-based tumor targeted NDDS which consist of PEG modified SWCNT 
functionalized with folic acid as a targeting group for the targeted delivery of 
anticancer drug doxorubicin (DOX). Doxorubicin is a broad-spectrum anti-cancer 
drug. Although it continues to be used extensively in the treatment of different 
cancers, its clinical value is limited due to the toxicity to healthy tissues. The aim of 
our work is to minimize the disadvantages of systemic administration of doxorubicin, 
which kills healthy cells. 32-34  
Folate receptors may be over-expressed on the surfaces of certain cancer cells. 
Therefore, folate-functionalized SWCNTs conjugated with the anticancer agent 
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become a highly desirable targeted drug delivery system. The folate-conjugated drug 
has shown the ability to be transported via endocytosis, get released in the cell and 
finally cause apoptosis and cell death. 35-38. 
 
Experimental section 
The SWCNTs (length 0.5- 100 µm, diameter of 1-2 nm), DSPE-PEG2000-NH2-FA 
(1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene-glycol-2000) 
folate), DSPE-PEG2000-NH2(1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
amine (polyethylene glycol) 2000), and Doxorubicin Hydrochloride was obtained 
from Wako Chemicals (Osaka, Japan). All reagents were purchased from Fisher 
Scientific (Fairlawn, NJ). Chemicals for cell culturing work - Lyso-tracker, Trypan 
Blue, Trypsin (0.25%), Dulbecco’s modified Eagle’s medium (DMEM) and fetal 
bovine serum (FBS) were purchased from Sigma-Aldrich, USA and Gibco, Japan. 
Invitrogen (USA, Japan) supplied Alamar Blue stain. 
Purification of SWCNTs 
Purification of SWCNTs was carried out according to previously reported procedure. 
39 The SWCNTs (30 mg) were added to a solution containing 96% H2SO4 and 70% 
HNO3 (3:1, V/V; 120 mL) and subjected to sonication at 0˚C for 24 h. Then the 
SWCNTs were thoroughly washed with deionized water and filtered through a micro-
porous filtration membrane (0.22 µm). After filtration, they were redispersed in HNO3 
(2.6 M, 200 mL) and refluxed for 24 h, collected by filtration and washed with 
ultrapure water to neutrality. The obtained product was then dried at 50°C for 24 h. 
Synthesis of PEGylated SWCNTs 
 Purified SWCNTs (0.2 mg) were sonicated in (0.10 mL) of dimethyl formamide 
(DMF) for 2 h to give a homogenous suspension. Oxalyl chloride (0.008 mL) was 
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added drop wise to the purified SWCNT suspension at 0˚C under N2 atmosphere. The 
mixture was stirred at 0˚C for 2 h and then at room temperature for another 2 h. 
Finally, the temperature was raised to 70˚C and the mixture was stirred overnight on a 
magnetic stirrer to remove excess oxalyl chloride. Folate conjugated PEG (FA-PEG) 
dispersed in chloroform and methanol was used for bio-conjugation. FA-PEG (0.2 
mM) was added to the SWCNT suspension and the mixture was stirred at 100˚C for 5 
days. After it was cooled to room temperature, the mixture was filtered through a 0.2 
µm pore-size membrane and washed thoroughly with ethyl alcohol and deionized 
water (DI). The PEGylated SWCNTs were collected on the membrane and dried 
overnight under vacuum.40 
DOX loading onto the PEGylated SWCNTs 
DOX loaded PEGylated nanotubes were prepared for anticancer treatment. The drug 
loading efficiency and its release profile from the PEGylated nanotubes were studied. 
Doxorubicin hydrochloride (15 mg) was stirred with the PEGylated nanotubes (5 mg) 
dispersed in a PBS (Phosphate buffered saline) buffered solution of pH 7.4 (10 mL) 
and stirred for 16 h at room temperature in dark condition to generate the targeted 
drug delivery system (DOX-FA-PEG-SWCNTs). Unbound excess DOX was removed 
by repeated centrifugation and washing with water until the filtrate was no longer red 
(red color corresponds to free DOX). Then the resulting DOX-FA-PEG-SWCNT 
complexes were finally centrifuged at 12,000 rpm for 10 min, the supernatant was 
decanted and the DOX-FA-PEG-SWCNT complexes were freeze dried.36 
Characterization of the modified nanotubes 
 Morphological features of pristine and purified SWCNTs were characterized using 
field emission transmission electron microscope (TEM) (JEM 2200 FS, JEOL, Japan). 
One drop of nanotube suspension was dropped on carbon coated copper grid after 
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hydrophilizing the grid for 30 s in TEM grid hydrophilizer (JEOL DATUM, HDT-
400) and dried thoroughly. Nanotubes were observed using TEM at 200 kV and the 
tubular nature of the SWCNTs were observed and images were recorded. Surface 
characteristics of the nanotubes were analyzed using scanning electron microscope 
(SEM) (JSM 7400F, JEOL, Japan). Nanotube samples were prepared on silica 
substrates and were sputter coated with platinum by an Auto Fine Coater (JEOL, 
Tokyo, Japan) for 50 seconds then the silica substrates were fixed to sample stubs 
using double-sided carbon tape, and were viewed at an accelerating voltage of 3-5 kV 
under SEM. For atomic force microscopy (AFM), the sample was deposited on a 
glass surface and vacuum dried. Tapping mode of the cantilever was used in the AFM 
analysis (MFP-3D-CF AFM, Asylum Research, USA). The presence of FA-PEG on 
FA-PEG-SWCNT was confirmed by studying the characteristic absorption peaks 
associated with functional groups of SWCNT, folic acid and PEG using X-ray 
photoelectron spectroscopy (XPS) (AXIS His-165 Ultra, Kratos Analytical, Shimadzu 
Corporation, Japan). Analysis was carried out under a basic pressure of 1.7x10-8 Torr 
and the X-ray source used was anode mono-Al with pass energy of 40. XPS spectra 
for FA-PEG-SWCNT with peaks of C, O and N were obtained. The zeta potential 
(Zetasizer Nano, Malvern Instruments Ltd.) of pristine SWCNT, purified SWCNT 
and PEGylated SWCNT was analyzed to confirm the change in their surface potential 
occurring due to the proper bio-functionalization. The DOX conjugation to the 
PEGylated SWCNTs was determined by UV/Vis absorption spectrophotometry (UV-
3100, Shimadzu, Japan). 
Drug loading efficiency analysis 
The amount of DOX loaded onto the PEGylated nanotubes was quantified41 
spectrophotometrically with the help of UV/Vis absorption spectroscope at an 
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absorbance of 490 nm based on a standard curve of DOX.42 Initially, a standard 
absorbance curve was plotted using standard concentrations of DOX in PBS solution 
to determine the exact amount of the drug loaded onto the nanotubes (data not 
shown). To calculate the loading efficiency of the drug, 100 µL of the drug-loaded 
samples were drawn before and after centrifugation step and analyzed. The following 
formula was used for calculating the drug efficiency:  
 
 
 
where, A total drug is the initial drug concentration and A free drug is the free drug 
concentration in the supernatant. 
In vitro drug release studies 
The in vitro drug release profile of DOX from DOX-PEG-SWCNT was studied at the 
physiological temperature of 37°C and pH of 7.4, 5.3 and 4.0 in PBS. The pH 5.3 and 
4.0 (the endosomal pH of cancer cells) and pH 7.4 (the physiological pH) were 
selected for in vitro drug release studies. All experiments were performed in 
triplicates. Suspensions of the DOX-loaded SWCNTs (1 mg) were prepared in 5 mL, 
of phosphate buffer solutions and maintained at 37°C under a continuous shaking of 
100 rpm for 3 days. At predetermined intervals, 1 mL of the sample supernatant was 
collected and centrifuged and the concentration of released DOX in the supernatant 
was estimated by UV/Vis spectrophotometer at 490 nm. At the same time, the 
suspension was compensated with 1 mL of fresh PBS. The concentration of drug 
released at a given time was calculated using a DOX standard curve.  
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Cell culture studies  
Breast cancer cell lines (MCF7) and mouse fibroblast cell lines (L929) cells, obtained 
from Riken bioresource Center, Japan were cultured in monolayers to 80% 
confluence by maintaining in Dulbecco’s minimal essential medium (DMEM, Gibco) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin 
solution in a 5% CO2 -humidified atmosphere at 37 °C. For use in experiments, 1 x 
104 cells/mL per well were seeded in glass based dish for confocal studies, 
approximately 5000-7000 cells were seeded in 96 well plates for cytotoxic studies, 
3×104 cells were plated in 25 mL flask for phase contrast studies.  
Biocompatibility studies of PEGylated SWCNTs  
Biocompatibility studies were carried out using phase contrast microscopy and 
Alamar blue assay. Phase contrast microscopy was studied to analyze the 
biocompatibility of the PEGylated nanotubes. MCF7 and L929 cells were plated onto 
6 well plates and the plates were incubated at 37°C in CO2 incubator with 5% CO2 
and allowed to grow to 70% confluency. The PEGylated nanotubes were added at a 
concentration of 0.1 mg/mL on day 2. The cells were again incubated for 24 h and 
washed before viewing under inverted phase contrast microscope (TE2000-U, Nikon 
ECLIPSE, Japan). 
 The biocompatibility of pristine and PEGylated nanotubes was also estimated by 
Alamar blue assay. Three different concentrations (0.1, 0.5 and 1.0 mg/mL) of 
pristine and PEGylated nanotubes were dispersed in PBS and treated with MCF7 and 
L929 cells grown in 96 well microplate for 24 h. After the addition of the nanotubes, 
these plates were further incubated for 24 h. After the addition of 10% Alamar blue 
dye to each well, the plates were incubated for 4 h and the viability was assessed 
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using a microplate reader (Multidetection microplate scanner, Dianippon Sumitomo 
Pharma, Japan) by measuring the absorbance and fluorescence intensity of the 
resultant product. Experiments were conducted in triplicates. 
In vitro cytotoxicity studies 
The in vitro cytotoxicity profile of the DOX-FA-PEG-SWCNT in comparison with 
free DOX was studied using Alamar Blue assay. MCF7 cells were exposed to three 
different concentrations (0.1, 0.5 and 1.0 mg/mL) for the above two samples for 72 h. 
Experiments were conducted in triplicates. Alamar blue assay evaluates the 
proliferation and metabolic activity of cells. In living cells, the mitochondrial 
reductase enzymes are active and reduce Alamar blue to form a different colored 
product form the blue dye. This reducing ability of the cells explains the active 
metabolism that takes place within the cells. When the samples added to the cells are 
toxic in nature, the reducing ability of the cells to reduce the dye decreases. The 
fluorescence intensity of Alamar blue assay was quantified at 590- 620 nm. 5000-
7000 cells per well were plated and incubated for 24 h before the addition of the 
nanoparticles. The nanoparticles dissolved in media were added and incubated for 24 
h and assayed. The experiment was conducted in triplicate and the viability was 
assessed using a microplate reader (Multidetection microplate scanner, Dianippon 
Sumitomo Pharm) by measuring the absorbance and fluorescence intensity of the 
resultant product.  
The relative cell viability was calculated using the formula: 
 
where, A sample is the absorbance of the sample used and A control is the absorbance 
of control sample. 
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Confocal microscopy 
The uptake of nanoparticles was studied using confocal microscopy. All the images 
were taken using a 100X oil immersion objective lens. Cells were seeded in a glass 
base dish with standard medium and incubated at 37ºC. After 24 hours of growth, 
nanoparticles both targeted and non-targeted, at a fixed concentration of 0.1 mg/mL 
were added to the cells and incubated for 2 hours at 37ºC for uptake by the cells. At 
the end of the incubation period, the nutrient media was removed and the cells were 
washed with PBS buffer (0.01 M, pH 7.4) thrice and stained with Lysotracker to mark 
the location of lysosomes within the cells to understand the localization of nanotubes 
within the cell. Fresh PBS (0.01 M, pH 7.4) buffer was added to the plates and the 
cells were viewed under confocal microscopy (Leica TCS SP5, Leica Microsystems 
GmbH, Germany) or (Olympus 1x81 under DU897 mode). 
 
Results and Discussions  
Nanotube characterization analysis 
An ideal NDDS should have high drug loading capability, strong affinity for target 
cells and should release drugs triggered by a characteristic feature of the diseased 
cells, thus improving the efficacy of the drug and minimizing the systemic toxicity. 
Here, the SWCNTs were purified before using as delivery vehicles for chemotherapy 
as the metal catalysts used for the synthesis of CNTs have been proven to be toxic. 
The SWCNTs can be purified or surface modified by exposing them to oxidizing 
conditions (solutions containing sulfuric acid and nitric acid). This results in the 
formation of carboxylic groups on the surface of SWCNTs, which increases their 
dispersibility in aqueous solutions.  
By TEM and SEM observations, we found that the purified nanotubes are dispersed 
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individually or in small bundles as compared with pristine SWCNTs, which were 
bundled, and aggregated with black metal catalyst and amorphous carbon particles. 
We have observed a concomitant decrease in the quantity of metal particles and 
amorphous carbon in the purified nanotubes when compared to pristine SWCNTs 
(Figure 1a- d) and (Figure 2a and b) respectively. 
To analyze the effect of PEGylation on the morphology of SWCNTs, we carried out 
SEM and AFM analysis of the PEGylated SWCNTs. On SEM and AFM analysis, we 
observed uniformly distributed PEGylated SWCNTs (Figure 3a and b). These pictures 
clearly showed that PEGylated SWCNTs are well dispersed and distributed. 
                            
 
2 0  nm
 
 
Figure 1. Transmission electron microscopy images of (a, b) Pristine and (c, d) 
Purified SWCNTs. 
d	  c	  
b	  a	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Figure 2. Scanning electron microscopy images of (a) Pristine and (b) Purified 
SWCNTs.  
 
    
Figure 3. (a) Scanning electron microscopy and (b) atomic force microscopy images 
of PEGylated SWCNTs. 
 
Particles  Zeta potential 
Pristine SWCNT -26.9 mV 
Purified SWCNT -54.2 mV 
PEGylated SWCNT -34.2 mV 
 
Table 1. Zeta potential analysis of pristine, purified and PEGylated SWCNTs. 
 
a	   b	  
a	   b	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To study the change in the surface properties of the modified SWCNTs by PEG 
coating, we have analyzed the zeta potential of the pristine, purified and PEGylated 
nanotubes. The zeta potential is an indicator of the stability of colloidal systems. The 
pristine SWCNTs have a zeta potential of -26.9 mV. The zeta potential was increased 
to -54.2 mV in purified SWCNTs and this may be due to the existence of many COO- 
groups on the sidewalls of SWCNTs.36 The PEGylated SWCNTs showed a zeta 
potential of -34.2 mV. PEGylated SWCNTs has less negative potential than purified 
SWCNTs since PEGylation converts the carboxylic acid groups into esters.40 The 
solubility of biofunctionalized SWCNTs was increased, presumably due to oxygen 
containing glycol chain, which can form hydrogen bonds with the water molecules 
and capture cations present in the solution.40 The shift towards more negative 
potential for PEGylated SWCNTs clearly proves the conjugation of PEG moieties on 
to the SWCNTs. 
Electron Spectroscopy for Chemical Analysis (ESCA) was used to confirm the 
presence of functional groups on the oxidized SWCNTs. The attachment of FA-PEG 
to oxidized SWCNTs was confirmed by N2 peak. The wide spectrum obtained clearly 
shows the peaks corresponding to carbon, oxygen and nitrogen. Nitrogen peak is 
absent in oxidized SWCNTs and the presence of nitrogen peak in the PEGylated 
SWCNTs43 confirms the PEGylation of the oxidized SWCNTs (Figure 4). 
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Figure 4. X-ray photoelectron spectroscopy (XPS) peaks of the SWCNTs. (a) Wide 
scan spectra of Pristine SWCNT (b) Purified SWCNT (c) PEGylated SWCNT. Inset 
corresponds to N1s signal spectra of PEGylated SWCNTs that has been shown 
separately outside. 
 
DOX loading onto the PEGylated nanotubes 
DOX loading onto the PEGylated SWCNTs was monitored by UV-Vis absorption 
spectroscopy. Figure 5 shows the absorption spectra of pristine SWCNT, plain DOX 
and DOX loaded onto PEGylated SWCNTs. Plain DOX in water displays absorption 
at 490 nm. The stacking of DOX onto PEGylated nanotubes was evident from the 
UV-Vis spectrum, which clearly shows the characteristic absorption peaks of DOX 
indicative of the interaction between DOX and SWCNTs.41 
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Figure 5. UV-Vis absorbance spectra of pristine SWCNT, plain DOX, DOX-FA-
PEG-SWCNT and DOX-PEG-SWCNT. 
 
Drug loading efficiency studies 
The loading of DOX onto the nanotubes can be determined by the analysis of the 
supernatant for free drug using UV-Vis spectrophotometer after ultracentrifugation of 
the DOX loaded SWCNTs. We obtained a DOX loading efficiency of 58% onto the 
PEGylated nanotubes. 
In vitro drug release studies 
The drug release profile of DOX from the DOX loaded nanotubes was studied at 
37°C in PBS at three different pH conditions 7.4, 5.3 and 4.0, with a continuous 
shaking of 100 rpm for 72 h. The temperature of 37ºC was selected for drug release 
response because it is close to the physiological temperature. The pH of 7.4 
corresponds to physiological pH and pH of 4.0 and 5.3 corresponds to lysosomal pH 
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of cancer cells. The drug release curves (Figure 6) indicate that the release of DOX 
from the PEGylated nanotubes is pH triggered, and the drug release studies were 
carried out till it reached the stationary phase. At pH 7.4, the drug release curve shows 
that DOX loaded on SWCNTs is released at a very low and slow rate for 6 h and 
attains a stationary phase in the ensuing hours with very minimum drug release up to 
24 h. However, at pH 4.0, the DOX release rate has been significantly enhanced 
during the initial 6 h. We have observed an initial burst of drug release up to 4 h 
followed by a sustained release pattern till 12 h. The above drug release pattern was 
repeated again with a small burst of drug after 12 h and again followed by a sustained 
release till 72 h. The drug release profile at pH 5.3 overlapped with that of pH 4.0. 
The above results can be ascribed to the hydrogen-bonding interaction between DOX 
and SWCNT, which is stronger under neutral conditions, resulting in a controlled 
release. However, the drug release pattern under acidic media indicates higher amount 
of DOX release than at neutral conditions. Under acidic conditions, the amine (-NH2) 
groups of DOX get protonated resulting in the partial dissociation of hydrogen-
bonding interaction; hence the amount of DOX released from SWCNTs is much 
higher. This efficient loading and release of DOX indicates strong π-π stacking 
interaction between SWCNTs and DOX.44, 45 
The loading and release of DOX depends upon the hydrogen bonding interaction with 
SWCNT and is a function of pH. At pH 7.4, four possibilities of hydrogen bonding 
have been expected: (a) -COOH of SWCNT and -OH of DOX, (b) -COOH of 
SWCNT and the -NH2 of DOX, (c) -OH of SWCNT and -OH of DOX and (d) -OH of 
SWCNT and -NH2 of DOX. This overall hydrogen bonding interaction between 
SWCNT and DOX is higher at pH 7.4.44, 41 Under acidic conditions, two kinds of 
hydrogen bonding can be expected (a) -COOH of SWCNT and-OH of DOX, and (b) 
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between -OH of SWCNT and the -OH of DOX. Also the -NH2 of DOX forms -NH3+ 
with H+, which cannot participate in hydrogen bonding. Furthermore, at low pH the 
H+ in solution would compete with the hydrogen bond forming group and weaken the 
above outlined hydrogen bonding interaction, which may lead to a greater release of 
DOX.44 Around 70% of the drug was released within 72 h in pH 4.0 buffer, whereas 
only 17% of the drug was released in pH 7.4 buffer indicating a higher percentage of 
release of DOX under acidic conditions. In summary, the FA-PEG-SWCNT displayed 
pH sensitive release of DOX, suggesting it to be a promising delivery vehicle for the 
anticancer drug, and showing potential for tumor targeting and controlled release 
applications. 
Biocompatibility studies 
Phase contrast studies were carried out to analyze the biocompatibility of 
functionalized SWCNTs. L929 cells and MCF7 cells were plated onto 6 well plates 
until it attained 70% confluency. Pristine SWCNTs and PEGylated SWCNTs (PEG-
SWCNT) at a concentration of 0.1 mg/mL was added to each well and the plates were 
incubated for 24 h. The biocompatibility of the functionalized SWCNTs can be seen 
in the phase contrast images taken after 24 h in Figure 7 (a-f). The image clearly 
shows the PEGylated SWCNT treated cells growing competently at par with the 
control cells. However, some dead cells were observed in the cells treated with 
pristine SWCNTs. The biocompatibility of the pristine and PEGylated nanotubes was 
further studied using Alamar blue assay (Figure 8). The above-mentioned samples 
were incubated with L929 cells and MCF7 for 24 h. The viability of L929 cells and 
MCF7 when treated with the highest concentration of 1 mg/mL of pristine SWCNT 
were found to be 64% and 59% respectively. However, the viability of the cells 
increased to 87% and 84% in L929 and MCF7 cells, when treated with the same 
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highest concentration i.e., 1 mg/mL of PEGylated SWCNTs thereby, indicating 
successful PEGylation of the SWCNTs with PEG. Thus, we can confirm that the 
PEGylated SWCNTs are highly biocompatible and least cytotoxic in nature. 
 
 
Figure 6. In vitro drug release profile of DOX from DOX-FA-PEG-SWCNT in 
phosphate buffered saline at pH 7.4, 5.3 and 4.0. 
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                                  L929 Cells                               MCF7 Cells 
   
                  
                    
 
Figure 7. Phase contrast microscopic images of normal (L929) and cancer (MCF7) 
cells treated with pristine SWCNTs and PEGylated SWCNTs after 24h. Control 
images of  (a) L929 and (b) MCF7 cells.  (c & d) are images of cells treated with 
pristine SWCNTs. (e & f) are images of cells treated with PEGylated SWCNTS and 
showing biocompatibility of cells after 24h of incubation. 
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Figure 8. Results of Alamar blue assay. Both (a) normal cells L929 and (b) cancer 
cells MCF7 were treated with different concentrations of Pristine SWCNTs and 
PEGylated SWCNTs. 
 
Confocal studies 
To confirm the cellular uptake of particles and their localization within the cells, 
confocal laser scanning microscopy was performed. The DOX-FA-PEG-SWCNTs 
and DOX-PEG-SWNTs were incubated with human breast cancer cells and analyzed 
by fluorescence microscopy allowing the DOX to be located as it emits red 
fluorescence under irradiation. To further elucidate the endosome-mediated pathway 
of the nanotubes, lysosomal staining was performed with green colored Lysotracker. 
The overlapping signals of red signal from the DOX-FA-PEG-SWCNT and green 
signal from lysosomes confirm the receptor-mediated endosomal uptake of the 
nanotubes into the cells. High targeting capability is vital for the selective destruction 
of cancer cells. It means that the targeting agents would bind to cancer cells at a much 
higher rate than to normal cells. To demonstrate the targeted delivery of DOX by 
SWCNTs, we conjugated folate as the targeting moiety that targets folate receptors of 
cancer cells. Increased DOX fluorescence was observed in MCF7 cells with DOX-
FA-PEG-SWCNT, compared to L929 cells, which showed minimum internalization 
b a 
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of the nanotubes (Figure 9). Thus, it indicates that the FA conjugated nanotubes is 
taken up more efficiently into the MCF7 cells and suggests that the DOX-FA-PEG-
SWCNT is internalized via the FA receptor mediated pathway, pointing to the 
significant role of folate in cellular uptake.  
In vitro cytotoxicity studies 
In vitro cytotoxicity profile of the DOX-FA-PEG-SWCNT in comparison with free 
DOX was studied using Alamar Blue assay. MCF7 cells were used for the 
cytotoxicity analyses. Three different concentrations of each of the DOX-FA-PEG-
SWCNT and DOX as test sample were used. The assays were carried out for 72 h and 
the fluorescence and absorbance readings were taken for analyses. Figure 10 a and b 
show	   the percentage of cell viability measured for free DOX and DOX-FA-PEG-
SWCNTs respectively, using Alamar blue assay. In the case of DOX-FA-PEG-
SWCNT, we observed that the cell viability decreased with increasing concentration 
for the initial 24 h. After 24 h, there was sustained release of drug resulting in a 
slower mortality rate. The viability was abruptly reduced to 59% even at the lowest 
concentration (0.1 mg/mL) in 24 h. The viability of the cancer cells was further 
decreased to 29% in 72 h at the same minimum concentration. DOX-FA-PEG-
SWCNTs induced serious cytotoxicity, even at a dose much lower than free DOX. In 
the following study, when 1mg/mL of free DOX was used, cell viability was 75% 
after 24 h and 63% of cells were viable after 72 h. This is because the permeability of 
cells to free DOX is very poor, and so cannot effectively kill the cancer cells. We also 
found that with increase in concentration, the viability of DOX-FA-PEG-SWCNTs 
treated cells decreased apparently, indicating that the therapeutic efficiency of DOX-
FA-PEG-SWCNT was dosage dependent.  
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Figure 9. Confocal laser scanning microscopy (CLSM) images showing the selective 
internalization of SWCNTs by L929 and MCF7 cells. (a, d, g) Bright field images of 
the cells treated with nanotubes, (b, e, h) shows the green fluorescence of the 
lysosomal staining of the cells with Lysotracker dye, (c, f, i) shows the red 
fluorescence images of cells internalized with DOX conjugated nanotubes.  
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The high efficiency of DOX-FA-PEG-SWCNTs may be due to the following reasons: 
(1) the folate attached SWCNTs could target the DOX-FA-PEG-SWCNTs conjugates 
to the targeted sites while free DOX is non-specific and damages normal tissues 
leading to serious side effects,44, 36 (2) DOX could easily enter cancer cells after 
conjugation onto SWCNTs because of their high cell membrane permeability,46, 47 and 
(3) the release of DOX from the SWCNTs is pH triggered which explains the abrupt 
decrease in cancer cell viability at 24 h and which then follows a slow drug release 
pattern and therefore, slower killing rates up to 72 h. From the results obtained, it can 
be concluded that DOX-FA-PEG-SWCNT proves to be the most cytotoxic to cancer 
cells, while not damaging the normal tissues, when compared to free DOX. 
 
 
Figure 10 (a). Results of Cytotoxicity Assay of 3 day study of plain DOX on MCF7 
cells. 
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 Figure 10 (b). Results of Cytotoxicity Assay of 3 day study of DOX-FA-PEG-
SWCNTS on MCF7 cells. 
 
Conclusion 
CNTs appear to accumulate in cancerous tumor tissues much more than in normal 
tissues, partly due to the enhanced permeability and retention (EPR) effect. In 
summary, we successfully synthesized a highly effective targeted NDDS based on 
PEG functionalized SWCNTs and then further functionalization was facilitated with a 
targeting group (FA) and an anticancer drug (Doxorubicin). The obtained system 
(DOX-FA-PEG-SWCNT) displays excellent stability under physiological conditions. 
It was found that it could also effectively release DOX at reduced pH typical of the 
tumor environment of intracellular lysosomes and endosomes. We conclude that this 
nanoscale drug delivery system is more selective and effective than the free drug and 
it should result in enhanced therapeutic effects, with reduced general toxicity and 
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hence reduced side effects in patients. Considering these positive in vitro drug 
delivery results, the application of DOX-FA-PEG-SWCNT could be extended to 
enhance the efficiency of cancer therapy in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   77	  
References 
1. GM Whitesides. et al. Nature Biotechnology. (2003) 21, 1161-1165. 
2. CR Lowe, et al. Current Opinion Chemical Biology. (2000) 10, 428-434. 
3. L Wang, W Zhao, W Tan. Nano Research. (2008) 1, 99-115. 
4.  Z Ji, G Lin, Q Lu, et al. Journal of Colloid Interface Science. (2012) 365,143-9. 
5. R Ravichandran. NanoBiotechnology. (2009) 5, 17. 
6. B Bob. Innovative Pharmaceutical technology. (2004) 1, 58. 
7. SK Sahoo, S Praveen, J Panda. Journal of Nanomedicine Nanotechnology Biology 
and Medicine. (2007) 3, 20. 
8. M Rawat, D Singh, S Saraf. Biological & pharmaceutical bulletin. (2006) 29,1790. 
9. XM Li, LY Ding, YL Xu, et al. International Journal of Pharmaceutics. 373 (2009) 
116. 
10. XB Xiong, ZS Ma, R Lai, A Lavasanifar. Biomaterials. 31 (2010) 165. 
11. ZH Xu, ZW Zhang, Y Chen, et al. Biomaterials. 31 (2010) 757. 
12. M Prabaharan, JJ Grailer, S Pilla, et al. Biomaterials. 30 (2009) 6065. 
13. K Kostarelos, A Bianco, M Prato. Nature Nanotechnology. 4 (2009) 627.  
14. M Prato, K Kostarelos, A Bianco. Accounts of Chemical Research. 41 (2008) 60. 
15. R Singh, JW Lillard. Experimental and Molecular Pathology. 86 (2009) 215. 
16. A Bianco, K Kostarelos, M Prato. Current Opinion Chemical Biology. 9 (2005) 
674. 38. 
17. PA Tran, LJ Zhang, TJ Webster. Advance Drug Delivery Reviews. 61 (2009) 1097. 
18. WR Yang, P Thordarson, JJ Gooding, et al. Nanotechnology. 18  (2007).  
19. SS Li, H He, QC Jiao, et al. Progress in Chemistry. 20 (2008) 1798. 
20. L Lacerda, A Bianco, M Prato, K Kostarelos. Journal of Material Chemistry. 18 
(2008) 17. 
	   78	  
21. Z Liu, S Tabakman, K Welsher, HJ Dai. Nano Research. 2 (2009) 85. 
22. XK Zhang, LJ Meng, QG Lu, et al. Biomaterials. 30 (2009) 6041. 
23. S Dhar, Z Liu, J Thomale, HJ Dai, et al. Journal of American Chemical Society. 
130 (2008) 11467. 
24. Z Liu, XM Sun, N Nakayama-Ratchford, HJ Dai. ACS Nano. 1 (2007) 50. 
25. NWS Kam, HJ Dai. Journal of American Chemical Society. 127 (2005) 6021. 
26. ID Rosca, F Watari, M Uo. Carbon. (2005) 43, 3124-3131. 
27. VC Moore, MS Strano, EH Haroz, RH Hauge. Nano Letters. (2003) 3, 1379-
1382. 
28. G Pastorin, W Wu, S Wieckowski et al. Chemical Communications. (2006) 1182-
4.  
29. B Massimo, R Nicola, B Nunzio. Biomacromolecules, (2011) 12, 3381–3393. 
30. MA Mamon, ME Itkis, S Niyogi, et al. Journal of American Chemical Society.  
(2001) 123, 11292-11293. 
31. JJ Sudimack, RJ Lee. Advance Drug Delivery Reviews. (2000) 41, 147-162. 
32. B Kalyanaraman, J Joseph, S Kalivendi, et al. Free Radical Research Center. 
(2002) 119-124. 
33. ME O'Brien, N Wigler, M Inbar, et al. Annals of oncology  (2004) 440-449. 
34. HL Wong, R Bendayan, AM Rauth, XY Wu. Journal of pharmaceutical sciences 
93 (8) (2004) 1993-2008. 
35. J Chen, S Chen, X Zhao, LV Kuznetsova. et al. Journal of American Chemical 
Society. (2008) 16778–16785.  
36. X Zhang, L Meng, Q Lu, Z Fei, PJ Dyson. (2009) 6041–6047,  
37. X Shi, H W Su, M Shen, et al. Biomacromolecules. 10 (2009) 1744–1750,  
38. R Li, R.Wu, L Zhao, et al. Carbon.  (2011) 1797–1805,  
	   79	  
39. J Liu, AG Rinzler, H Dai, JH Hafner, et al. Fullerene Pipes Science. (1998) 280, 
1253-1256. 
40. B Zhao, H Hu, A Yu, D Perea, et al. Journal of American Chemical Society. 
(2005) 127, 8197-8203. 
41. H Huang, Q Yuan, JS Shah, RDK Misra. Advanced Drug Delivery Reviews. 
(2011) 63, 1332-1339. 
42. YJ Gu, J Cheng, J Jin, SH Cheng, et al. International Journal of Nanomedicine 
(2011) 6, 2889-2898. 
43. S Chen, Y Jiang, Z Wang, et al. Langmuir. (2008) 24, 9233–9236. 
44. D Depan, J Shah, RDK Misra, J Shah. Materials science and engineering. (2011) 
C 31, 1305-1312. 
45. Z Liu, X Sun, N Nakayama-Ratchford, et al. ACS Nano. (2007). 1, 50–56. 
46. K Kostarelos, L Lacerda, G Pastorin, et al. Nature Nanotechnology. (2007) 2, 
108-13. 
47. JP Cheng, KAS Fernando, LM Veca, et al. ACS Nano. 2 (2008), 2085. 
 
 
 
 
 
 
 
 
 
 
	   80	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   81	  
        Chapter 4 
Accelerated killing of cancer cells using multifunctional SWCNTs 
based system for targeted drug delivery in combination with 
photothermal therapy 
 
Abstract 
The photothermal therapy using nano-materials has recently attracted attention as an 
efficient strategy for the next generation of cancer treatments. Single walled carbon 
nanotube (SWCNT) is an upcoming potent candidate for the photothermal therapeutic 
agent since it generates significant amounts of heat upon excitation with near-infrared 
light. Photothermal effect can be employed to induce thermal cell death in a 
noninvasive manner. Photothermal effect of single-walled carbon nanotubes 
(SWCNTs) in combination with an anticancer drug doxorubicin (DOX) for targeted 
and accelerated destruction of breast cancer cells has been demonstrated in this 
chapter. A targeted drug delivery system was developed for selective killing of breast 
cancer cells with polyethylene glycol (PEG) biofunctionalized and DOX loaded 
SWCNTs conjugated with folic acid (FA). SWCNTs have strong optical absorbance 
in the near-infrared (NIR) region. In this special spectral window, biological systems 
are highly transparent. Our study reports that under laser irradiation at 800 nm, 
SWCNTs exhibited strong light-heat transfer characteristics. These optical properties 
of SWCNTs open the way for selective photothermal ablation in cancer therapy. It 
was also observed that, the internalization and uptake of folate-conjugated nanotubes 
into cancer cells was achieved by a receptor mediated endocytosis mechanism. 
Results of the in vitro experiments show that laser was effective in destroying the 
cancer cells, while sparing the normal cells. When the above laser effect was 
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combined with DOX conjugated SWCNTs, we have found an enhanced and 
accelerated killing of breast cancer cells. Thus this nano drug delivery system 
(NDDS) consisting of laser, drug and SWCNTs, proves to be a promising selective 
modality with high treatment efficacy and low side effects for use as future cancer 
therapeutics. 
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Introduction 
Chemotherapy is used in cancer treatment to destroy cancer cells for maximum 
treatment efficacy but with side effects to healthy tissues.1 Although the medical 
science and biomedical engineering has advanced to a significant extent, the 
therapeutic development of anti-cancer strategies is still limited2 due to reduced 
solubility, poor non-selective biodistribution and restriction by dose-limiting toxicity. 
Thus, detecting cancer in its early stage, in combination with controlled and targeted 
therapeutics may provide a more efficient and less harmful solution to overcome the 
limitations of conventional techniques.3, 4 Nanomedicine, an emerging research area 
that integrates nanomaterials and biomedicine, has attracted increasing interest as 
novel therapeutic strategy in cancer. Nano drug delivery systems (NDDS) have been 
developed to overcome the above limitations and to improve the pharmacological and 
therapeutic effects of the anticancer drugs. NDDS provides advantages like site-
directed drug targeting5 for improving drug efficiency, decreased side effects, early 
stage cancer detection,6 improving the drug loading capacity and controlled drug 
release rates. A tumor targeted NDDS generally combines tumor recognition moiety 
with drug-loaded nanoparticles.7-13 In recent years, various nano-sized drug delivery 
vehicles have been evaluated14-16 of which carbon nanotubes17, 18 have been shown to 
be advantageous to cancer therapy and imaging. Single-walled carbon nanotubes 
(SWCNTs), which are thin sheets of benzene rings rolled up into seamless cylinders, 
have many unique physical and chemical properties and attracted significant attention 
as promising drug delivery nano-vehicles for cancer diagnosis and chemotherapy due 
to their advantages like remarkable cell membrane penetrability, high drug loading 
capacity, pH-dependent therapeutic unloading and prolonged circulation half-lives.19-
21 SWCNT based NDDS have already been investigated as potential delivery vehicles 
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for intracellular transport of nucleic acids,22, 23 proteins24-26 and drug molecules,27-30 
and it has been repeatedly and independently proven by many in vitro results that the 
multifunctional SWCNTs could greatly improve the therapeutic efficiency of the drug 
while reducing their toxicity.30-32 Thus, considering the advantages of SWCNTs, its 
potential as a nanocarrier for effective and safe transport for drug therapy is very 
promising. Carbon nanotubes especially SWCNTs, consisting of quasi one-
dimensional quantum wires,33 have many interesting inherent optical properties that 
can be useful in biomedical imaging.34-38 SWCNTs have strong optical absorption 
from UV to NIR regions, which can be utilized for photothermal therapy17, 35, 39, 40 and 
photoacoustic imaging41, 42 from the heat they generate from NIR light absorption. 
Semiconducting SWCNTs with small band gaps of the order of 1 eV show 
photoluminescence in the NIR to IR-A range, which covers the tissue transparency 
window, and is therefore suitable for fluorescence imaging in biological systems.43, 44 
Therefore, SWCNTs appear to be an excellent platform for biomedical molecular 
imaging. Photothermal therapy for cancer has been widely investigated as an ideal, 
local, non-invasive treatment approach in comparison with other methods,45 due to its 
precise energy delivery to target cells and the sensitivity of tumor cells to temperature 
elevation.46 Laser light in the near-infrared (NIR) region is highly beneficial for in 
vivo use because of the low absorbance of biological tissues in the NIR region, thus 
making it a more promising approach towards cancer cell destruction with negligible 
side effects to healthy tissues. In bio-nanotechnology based cancer therapy, 
nanostructures with unique photothermal properties have been considered for the 
destruction of cancer cells.17, 18, 29, 47, 48 The intrinsic properties of SWCNTs are 
suitable for these techniques, due to their strong optical absorbance in the NIR region, 
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which could release significant heat and enhance thermal destruction of cells during 
NIR laser irradiation.  
PEGylation is a common strategy to impart versatile functionalities, high water 
solubility, biocompatibility and prolonged circulation in blood. PEG is composed of 
repeating ethylene glycol units -(CH2-CH2-O)n-, where the integer ‘n’ is the degree of 
polymerization. PEG-coated SWCNTs are obtained by adsorption of amphiphilic 
polymer functionalized with activated PEG chains onto SWCNTs.49 This is highly 
desirable for biological applications because it reduces their non-specific uptake by 
cells within the recticulo-endothelial system, which diminishes their phagocytosis, 
thus leading to prolonged circulation time in blood.50 PEGylation of SWCNTs does 
not disrupt the π network of SWCNTs, thus preserving their physical properties, 
which are promising for multiple biomedical applications including imagining.3 
Doxorubicin is one of the first identified anthracyclines and was isolated from the 
pigment-producing Streptomyces peucetius in the 1960s. It is also known as 
adriamycin and hyrdoxydaunorubicin. Doxorubicin is an essential component in the 
treatment of a wide variety of cancers, including hematological malignancies, many 
types of carcinoma and soft tissue sarcomas. The mechanisms of action of 
doxorubicin in cancer cells is brought about by the intercalation of doxorubicin into 
DNA base pairs, which inhibits the progression of the enzyme, topoisomerase II, to 
stabilize topoisomerase II complex and eventually impedes DNA resealing. The 
resulting DNA fragmentation leads to cell death.51-53 However, the clinical use of 
doxorubicin soon proved to be hampered by serious problems such as the 
development of resistance in tumor cells or toxicity in healthy tissues. The 
development of effective approaches to limit toxicity to normal cells while 
maintaining a high anti-cancer efficacy of doxorubicin in tumor cells has become a 
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focus in recent years with efforts being made to develop tumor-targeted formulations.  
 Folate (FA) as targeting moiety was selected, since folate receptors are over 
expressed on many tumors including ovarian, breast, brain, kidney, lung and liver. 55 
The nanoparticles-folic acid conjugates have shown the ability to enter some tumor 
cells via the folic acid receptor mediated pathway,54-58 and following internalization; 
the drug is selectively released into the acidic environment of the lysosomes and 
endosomes.3 The uptake of folate-conjugated SWCNTs into cancer cells was 
investigated using confocal fluorescence imaging. In vitro cytotoxicity of PEGylated 
SWCNTs conjugated with folate as a targeting moiety and loaded with an anticancer 
drug doxorubicin along with laser irradiation were tested in MCF7 cells.  
The ability to kill tumor cells by our system (DOX-FA-PEG-SWCNT) has been 
further enhanced through NIR irradiation mediated targeted cancer destruction by 
using the photothermal effect of the SWCNTs. This approach, which uses a 
combination of DOX and photothermal properties of SWCNTs, might provide a 
mechanism for enhanced cancer therapy and biological imaging applications. 
 
Experimental details 
The SWCNTs (length 0.5- 100 µm, diameter of 1-2 nm), fluorescein-FA-PEG and 
fluorescein-PEG-amine were obtained from Sigma Aldrich, Japan. Doxorubicin 
Hydrochloride was obtained from Wako Chemicals (Osaka, Japan). Concentrated 
acids and all other reagents were purchased from Fisher Scientific (Fairlawn, NJ). 
Chemicals for cell culturing work - Lyso-tracker, Trypan Blue, Trypsin (0.25%), 
Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were 
purchased from Sigma-Aldrich, USA and Gibco, Japan. Alamar Blue toxicology kit 
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was purchased from Invitrogen, USA. All chemicals used for this work were of 
reagent grade. 
Preparation and characterization of DOX loaded SWCNTs 
A SWCNT-based tumor targeted NDDS which consist of PEG modified SWCNT 
functionalized with folic acid as a targeting group for the targeted delivery of 
anticancer drug doxorubicin (DOX) was developed and characterized as previously 
described in Chapter 3. 
Synthesis of fluorescent SWCNTs  
FITC-FA-PEG was used to label SWCNTs. FITC-FA-PEG (1 mM) was sonicated 
with 0.25 mg/mL of SWCNTs in water for 1 h, and the resulting black suspension 
was centrifuged at 25,000 g for 6 h. The pellet formed at the bottom of the centrifuge 
tube containing aggregated CNTs and impurities were discarded. The supernatant was 
collected and filtered through a centrifugal filter (100 kDa molecular weight cut off, 
Millipore Amicom). The sample was washed several times with water to remove the 
excess PEGylated fluorescein and re-suspended in water and stored for further NIR 
laser studies.59 UV-Vis measurements of FITC- FA-PEG-SWCNT, SWCNT and 
FITC-FA-PEG were carried out. 
Laser measurements 
For in vitro experiments, SWCNT solution were irradiated by 800 nm laser at 0.5-1 
W/cm2 for 3 min, and the temperature was measured with an infrared thermal camera 
(TVS200EX, NEC, Japan). All the experiments were conducted at room temperature. 
Cell culture studies  
Breast adenocarcinoma cells (MCF7) and mouse connective tissue (L929) fibroblast 
cells were procured from RIKEN Bioresource Center, Japan. Breast cancer cell lines 
(MCF7) and mouse fibroblast cell lines (L929) were cultivated for in vitro 
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experimental studies. MCF7 cells and L929 cells were cultured in T25 flasks and 
maintained separately in monolayers to 80% confluence using DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin solution in a 5% CO2 humidified 
atmosphere at 37°C.  For use in experiments, the respective cells were trypsinized, 
counted and loaded onto their respective plates for testing. Cells were seeded into 96 
well plates for cytotoxic studies and in 33 mm glass base dish for confocal studies. 
For cytotoxicity studies, 5000 cells/well were seeded and for confocal studies, 30,000 
cells/glass base dish were plated and grown for 24 h before treating them with the 
nanoparticles. 
Alamar blue assay evaluates the proliferation and metabolic activity of cells. In living 
cells, the mitochondrial reductase enzymes are active and reduce blue colored Alamar 
blue to a different colored product. This reducing ability of the cells explains the 
active metabolism that takes place within the cells. When the samples added to the 
cells are toxic in nature, the reducing ability of the cells to reduce the dye decreases. 
The fluorescence intensity of Alamar blue assay was quantified at 590- 620 nm. 
Selective internalization of SWCNTs into cancer cells 
The internalization of the nanotubes with cancer MCF7 and control L929 cells were 
studied using confocal laser scanning microscopy. Cells were seeded in a glass base 
dish with standard medium and incubated at 37ºC for imaging studies. After 24 hours 
of growth, 0.1 mg/mL of DOX-PEG-SWCNT and DOX-FA-PEG-SWCNT nanotubes 
were suspended in the medium and from the above concentration 20 µL were taken 
and added to the cells and incubated for different time intervals (1, 3 and 5 h) at 37ºC 
for uptake by the cells. At the end of the incubation period, the media was removed 
and the cells were washed thrice with PBS buffer. To mark the location of lysosomes 
within the cells and to understand the localization of nanotubes within the cells, the 
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cells were stained with Lysotracker as per the manufacturer’s instructions. In addition, 
the endosome-mediated uptake of the nanotubes was also confirmed. All the images 
were taken using a 100X oil immersion objective lens.  The cells were viewed under a 
confocal microscope (Olympus 1X 81 in DU897 mode). Emission filter of 561/488 
nm were used to observe the fluorescence emitted by the DOX conjugated nanotubes 
and Lysotracker. 
Cancer destruction using the NIR effect of SWCNTs 
In this study, we explored the effects of irradiation using an 800 nm laser on FITC-
FA-PEG-SWCNT. The accelerated and combined destructive effects of DOX-FA-
PEG-SWCNT on excitation with laser were analyzed. SWCNTs can efficiently 
convert 800 nm laser energy into heat, and selectively destroy target cells. The effect 
of NIR laser was studied using MCF7 cancer cell lines. Untreated cells were used as 
controls. Cells were seeded at a density of 1.6 X 104 cell/mL in 35 mm petri dishes. 
After 24 h of growth, MCF7 cells without SWCNT, with FITC-FA-PEG-SWCNT and 
DOX-FA-PEG-SWCNT at concentration of 0.1 mg/mL were added to the cells and 
again incubated for 3 h, rinsed with PBS, and stained with Lysotracker as per the 
manufacturer’s instructions. The cells were again washed and placed in fresh medium 
and irradiated by 800 nm laser at 0.5-1 W/cm2 for 3 min, and the temperature changes 
were recorded using an infrared thermal camera (TVS200EX, NEC, Japan). All the 
experiments were conducted at room temperature. The cells were viewed under 
confocal microscope before and after the laser treatments using a 100X oil objective 
and 488/561 nm excitations. 
In vitro cytotoxicity assays of nanotubes under laser irradiation 
The in vitro cytotoxicity profile of the MCF7 cells without SWCNTs and with FITC-
FA-PEG-SWCNT and DOX-FA-PEG-SWCNT after laser irradiation was studied 
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using Alamar Blue assay. MCF7 cells were exposed to 0.1 mg/mL of the 
functionalized SWCNTs for the above two samples. Untreated cells were used as 
controls. Experiments were conducted in triplicates. The experiments were carried out 
for a time interval of 6 h, 12 h and 24 h. The fluorescence intensity of Alamar blue 
assay was quantified at 590-620 nm. 
 
Results and Discussions  
An ideal NDDS should have high drug loading, strong affinity for target cells and 
should release drugs triggered by a characteristic feature of the diseased cells, thus 
improving the efficacy of the drug and minimizing the systemic toxicity. In this study, 
Figure 1 shows the schematic representation of a targeted drug delivery system based 
on SWCNTs, biofunctionalized with polyethylene glycol (PEG), conjugated with 
folic acid (FA) as targeting moiety and loaded with DOX for selective killing of 
tumor cells was developed. Also, the photothermal effect of SWCNTs in combination 
with an anticancer drug DOX for targeting and selective destruction of breast cancer 
cells is demonstrated. 
Characterization of the fluorescent SWCNTs 
The functionalization of SWCNTs with FITC-PEG was analyzed by UV-Vis 
absorption spectroscopy. Figure 2 a, b and c shows the absorption spectra of pristine 
SWCNTs, FITC-PEG and FITC-PEG-SWCNT. The absorbance peaks of FITC-PEG-
SWCNT at 250 nm and 550 nm corresponds to the characteristic peaks of SWCNT 
and FITC-PEG, respectively. 
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Figure 1. Schematic representation of an NDDS based on SWCNTs, 
biofunctionalized with PEG, conjugated with FA and loaded with DOX along with 
photothermal therapy for selective killing of tumor cells. 
 
a                                                  b                                             c 
 
Figure 2. UV-Vis spectra of (a) Pristine SWCNT (b) FITC-PEG (c) FITC-PEG-
SWCNT. 
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Temperature measurement during NIR radiation 
To detect the effects of 800 nm optical excitation of SWCNTs, we carried out two 
different sets of control experiments. First set was carried out by irradiating DMEM 
without and with SWCNTs, ex vitro. Three different nanotube concentrations (0.1, 
0.5 and 1 mg/mL) were selected. We observed that irradiation of DMEM without 
SWCNTs caused temperature increase from 20.1 to 20.5°C. However, DMEM with 
SWCNTs at 0.1, 0.5 and 1 mg/mL concentrations irradiated by 0.5-1 W/cm2, 800 nm 
laser for 3min caused the temperature to elevate from 21.4 to 45.3°C, 21.5 to 69.2°C 
and 21.1 to 85.7°C, respectively (Figure 3a). In the second set of experiment, MCF7 
cancer cells were seeded at a density of 1.6 X 104 cell/mL in 35 mm petri dishes. 
After 24 h of growth, MCF7 cells without SWCNTs and MCF7 cells with FITC-PEG-
SWCNT and FITC-FA-PEG-SWCNT at a concentration of 0.1 mg/mL were added to 
the cells and again incubated for 3 h, rinsed with PBS to remove the unbound 
SWCNTs, and followed by irradiation with a 800 nm laser for 3min. We observed a 
temperature increase from 20.6 to 20.8°C for MCF7 cells without SWCNTs, whereas 
temperature elevation from 21.3 to 26°C and 21 to 45.1°C for MCF7 cells with FITC-
PEG-SWCNT and with FITC-FA-PEG-SWCNT, respectively, were noted (Figure 
3b). These findings clearly demonstrated the strong light-heat transfer characteristics 
of the FITC-FA-PEG-SWCNT by 800 nm light. Also, the heating efficiency of FITC-
FA-PEG-SWCNT relies strongly on time and dose, indicating that with increasing 
concentration and time, the temperature was significantly higher. 
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Figure 3a. Plots of temperature increase for suspensions of SWCNTs at various 
concentrations as a function of irradiation time using laser at 0.5-1 W/cm2  for 3 min. 
 
Figure 3b. In vitro temperature measurements using SWCNTs at a concentration of 
0.1 mg/mL incubated with MCF7 cells during irradiation by an 800-nm laser at 0.5-1 
W/cm2  for 3 min. 
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Selective internalization of SWCNTs into cancer cells 
Receptor mediated endocytosis is the most common pathway of endocytosis.61, 62 It 
provides a means for the selective and efficient uptake of particles that may be present 
in the extracellular medium. Receptors are present on the cells for the uptake of 
different types of ligands like plasma proteins, enzymes, hormones and growth 
factors.63 Here we investigate the uptake of folate-conjugated nanotubes into MCF7 
cells that overexpresses folate receptors on the surface of cell membrane. The 
selective internalization and uptake of SWCNTs into cancer cells were recorded by 
confocal imaging to determine the intracellular fate of the nanotubes. Time-dependent 
cellular uptake of the nanotubes was studied for 1 h, 3 h and 5 h incubation periods 
(Figure 4a- f). After incubating the cells with DOX-FA-PEG-SWCNT for 1 h, the 
SWCNTs were initially seen attached to the plasma membrane of the cells, also the 
fluorescence intensity was very low. After 3 h of incubation, strong fluorescence was 
observed in the cytoplasm, indicating the entry of SWCNTs into cells. After 5 h, 
confocal images revealed decreased fluorescence inside cells, corresponding to the 
redistribution and discharge of SWCNTs out of the cells.62 No fluorescence was 
observed in the nucleus for all cells, indicating the lack of SWCNTs translocating into 
the nucleus. The selective uptake of DOX-PEG-FA-SWCNT inside cancer cells 
clearly indicates that the folate receptor mediated endocytosis is more selective and 
efficient than the nonspecific endocytosis. 
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 Figure 4.Confocal images of MCF7 cells treated with DOX-FA-PEG-SWCNTs at 
different incubation time intervals. (a, b, c) are bright field images of MCF7 cells and 
(d, e, f) are fluorescence images of MCF7 cells treated with DOX-FA-PEG-SWCNTs 
for 1, 3 and 5 h. 
 
Cancer destruction using the NIR effect of SWCNTs 
We have investigated the effects of SWCNTs on cancer cells during NIR laser 
treatment. After achieving confluence, MCF7 cells were incubated with FITC-PEG-
a	  
	   96	  
SWCNT and FITC-FA-PEG-SWCNT for 3 h, followed by irradiation with an 800 nm 
laser for 3 min. Figure 5 a- c shows the confocal images of MCF7 cells treated with 
FITC-PEG-SWCNT before and after laser irradiation. The images showed that the 
cells survived even after 3 min laser exposure, these results can be attributed to the 
low uptake of FITC-PEG-SWCNT into the MCF7 cells.  From the confocal images of 
cancer cells with FITC-FA-PEG-SWCNT uptake before and after laser treatment, as 
shown in Figure 6 a- c, we could easily observe the breaking of cancer cells due to the 
hyperthermia effects in FITC-FA-PEG-SWCNT treated cells under laser excitation. 
Before laser treatment, the MCF7 cells have a clear dividing line between the nucleus 
and the cytoplasm, and the cells remain essentially intact. The SWCNTs mainly 
localize in cytoplasm, as evidenced by the presence of green fluorescence in 
cytoplasm. After the laser treatment, it is difficult to distinguish between the 
cytoplasm and nucleus since all cancer cells show distorted morphology of cells 
undergoing apoptosis. Also, green fluorescence in the cells undergoing apoptosis can 
been seen inside whole cells, thus indicating the damage of nuclear envelope caused 
by the hyperthermia effect of SWCNTs under laser irradiation. These results clearly 
state the high selectivity of FITC-FA-PEG-SWCNT on the NIR destruction of cancer 
cells. The selective destruction of cancer cells was further analyzed by Alamar blue 
assay. The studies were carried out in three sets (a) cancer cells + laser, (b) cancer 
cells + FITC-PEG-SWCNT + laser and, (c) cancer cells + FITC-FA-PEG-SWCNT + 
laser. Untreated cells were used as controls. All cells were irradiated with an 800 nm 
laser for 3 mins. The experiments were carried out for a time interval of 6 h, 12 h and 
24 h. We observed that the cell viability of FITC-FA-PEG-SWCNT with laser 
treatment was 54, 27 and 5% at 6 h, 12 h and 24 h, respectively, when treated with a 
concentration of 0.1 mg/mL (Figure 7). The rate of viability of cells with only laser 
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treatment remained high, showing no obvious difference from the control group, 
indicating the NIR property of the laser where biological tissues are highly 
transparent. In case of cells treated with FITC-PEG-SWCNT, a high cell viability rate 
was observed. However the cell viability was drastically decreased in FITC-FA-PEG-
SWCNT treated cells. 
We also studied the combined cytotoxic effect of laser and DOX loaded SWCNTs. 
When the MCF7 cells were treated with DOX-FA-PEG-SWCNTs in the presence of 
laser irradiation for 3 min, the cell viability was reduced significantly. The confocal 
images clearly show apoptosis in the cancer cells treated with DOX-FA-PEG-
SWCNTs after 3min laser exposure (Figure 8 a- c). The reason for this may be that 
the cell tolerance drops dramatically at a certain temperature during heat treatment.58 
Also, laser treatment application might have triggered the release of drug from the 
DOX-PEG-FA-SWCNTs, resulting in increased cell death. The cytotoxic effect of 
DOX-PEG-FA-SWCNTs in combination with laser on MCF7 cells was further 
analyzed by Alamar blue assay (Figure 9). From the results shown in Table 1, 
significant reduction in cell viability was observed, and the cell viability was 37%, 
11% and 2% for 6 h, 12 h and 24 h, respectively. The inhibition rate of the cells under 
this mode was greater when compared to that of the cells treated with DOX free 
SWCNTs under laser. These results show that SWCNTs has a significant 
photothermal effect, and when combined with chemotherapy, it is ideal for cancer 
treatment, without causing toxicity to normal cells. 
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Figure 5. Confocal images of cancer cells (MCF7) treated with FITC-PEG-SWCNT 
(a) before laser treatment, (b) after 3 min laser treatment and viewed after 12 h, (c) 
confocal image viewed after 24 h. 
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Figure 6. Targeted destruction of cancer cells by SWCNTs photothermal effect. 
Confocal images of cancer cells (MCF7) treated with FITC-FA-PEG-SWCNT (a) 
before laser treatment, (b) after 3 min laser treatment and viewed after 12 h. (c) 
confocal image viewed after 24 h.  
 
Figure 7. Results of cytotoxicity assay of FITC-PEG-SWCNT and FITC-FA-PEG-
SWCNT after 3 min laser irradiation by an 800 nm laser on MCF7 cells.  
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Figure 8. Targeted destruction of cancer cells by the photothermal effect of SWCNTs. 
Confocal images of cancer cells (MCF7) treated with DOX-FA-PEG-SWCNT (a) 
before laser treatment, (b) confocal image after 3 min laser treatment and viewed after 
12 h (c) confocal image after 3 min laser treatment and viewed after 24 h.  
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Figure 9. Results of cytotoxicity assay of DOX-PEG-SWCNT and DOX-FA-PEG-
SWCNT after 3 min laser irradiation by an 800 nm laser on MCF7 cells.  
 
Sample/Time 6h 12h 24h 
Cancer cell + FITC-PEG-SWCNT + Laser 93% 89% 85% 
Cancer cell + FITC-FA-PEG-SWCNT + Laser 54% 27% 05% 
Cancer cell + DOX-PEG-SWCNT + Laser 93% 87% 83% 
Cancer cell + DOX-FA-PEG-SWCNT + Laser 37% 11% 02% 
 
Table 1. Results of Cytotoxicity Assay representing the percentage of cell viability of 
cancer cells treated with various modified SWCNTs at a concentration of 0.1 mg/mL 
after laser irradiation by an 800 nm laser at 0.5-1 W/cm2   for 3 min and studied up to 
24 h. 
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Conclusion 
An ideal NDDS against cancer is expected to enter and destroy cancer cells while 
minimizing the side effects to normal tissues. Our results show that FA functionalized 
SWCNTs could be selectively internalized into cancer cells via a folate-folate 
receptor mediated pathway, without internalization into normal cells. Along with this 
obtained system (DOX-FA-PEG-SWCNT), we further demonstrate a photothermal 
technique for targeted cancer destruction by using the photothermal effect of 
SWCNTs. SWCNTs has a high optical absorbance in the NIR region, where 
biological tissues are highly transparent. From the observation of our data, it is clear 
that SWCNTs act efficiently to convert laser energy into heat after exposure to 800 
nm laser irradiation in vitro. This advantage was used in selective photothermal 
therapy, for killing only cancer cells while sparing normal cells. Our results also 
showed that both, concentration of SWCNTs and time of laser, are controlling factors 
for thermally induced cytotoxicity. Also, the combined effect of targeted drug loaded 
DOX-FA-PEG-SWCNT with photothermal therapy was studied and we observed that 
the combined effect synergistically killed almost 95% of cancer cells at an accelerated 
rate. We conclude that this nanoscale drug delivery system is more selective and 
effective than the free drug, and results in enhanced therapeutic effects, when 
combined with photothermal therapy and reduced general toxicity. Considering these 
promising in vitro drug delivery results, the application of DOX-FA-PEG-SWCNT 
combined with NIR laser could be extended to enhance the efficiency of cancer 
therapy in the near future. 
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Chapter 5 
Co-delivery of dual drugs using multifunctional carbon nanotubes 
for cancer therapy 
 
Abstract 
 The use of single chemotherapeutic drug has shown some limitations in anti-tumor 
treatment, such as development of high toxicity, drug resistance, and limited regime 
of clinical uses. The combination of two or more therapeutic drugs is a feasible way 
to overcome the limitations of current treatment options. Co-delivery strategy has 
been proposed to minimize the amount of each drug and to achieve the synergistic 
effect in cancer treatment. Here, we present a dual drug delivery system consisting of 
PEG modified SWCNT conjugated with FA and loaded with two anticancer drugs 
doxorubicin (DOX) and paclitaxel (PTX). Independent and combined drug release 
behaviors of the drugs were studied. In vitro studies were done in MCF7 cells. A 
faster drug release was found to be associated with lower pH, which is advantageous 
for tumor targeted anticancer therapy. The nanocarrier containing the combination of 
anticancer drugs suppressed tumor cells growth more efficiently, demonstrating a 
highly synergistic anti-proliferative activity in MCF7 breast cancer cells. The effect of 
this DDS in combination with laser was also analyzed and enhanced destruction of 
breast cancer cells were observed. This nanocarrier seems to have important potential 
in clinical applications for co-delivery of multiple anti-tumor drugs with different 
properties. 
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Introduction 
Currently available technologies have made enormous advancement in cancer    
research, but an adequate therapy remains elusive.1 Existing chemotherapeutic drugs 
have disadvantages like severe undesirable side effects, low bioavailability or 
development of drug resistance. Overcoming these limitations requires effective 
delivery of chemotherapeutic drugs to tumor tissues with a minimal side effect to 
healthy tissues.2 Over the past few decades, drug delivery systems (DDSs) have been 
developed and studied in great depth to improve the curative effect of drugs.3-8 The 
discovery of carbon nanotubes has opened up new opportunities in the field of 
nanotechnology and nanoscience.9-11 The interesting properties of carbon nanotubes, 
such as stability, inertness, and higher surface area-to-volume ratio suggest the 
potential utility of these materials as carriers in drug delivery systems requiring higher 
loadings of therapeutic agents.12-14 The application of carbon nanotubes in drug 
delivery systems was apparent immediately after the first demonstration of the 
capacity of these materials to penetrate into cells.15 Several in vitro studies have 
demonstrated that carbon nanotubes can effectively transport various molecules 
including drugs, peptides, and proteins into cells.16-21 Modification of carbon 
nanotubes through functionalization of their external walls is a key step for 
biomedical applications because a wide variety of active molecules can be linked to a 
functionalized carbon nanotube.22-26 Due to the hydrophilicity of polyethylene glycol 
(PEG), this polymer is used to functionalize carbon nanotubes in drug delivery 
systems to prepare stealth nanoparticles which can escape the reticuloendothelial 
systems.27 Photothermal therapies for cancer have been widely investigated as a 
minimally invasive treatment modality in comparison with other methods. 28,29,30 
Biological systems are known to be highly transparent in the near-infrared light 
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(NIR). An intrinsic property of SWCNTs is their strong optical absorbance in the NIR 
region, which could release significant heat and enhance thermal destruction of cells 
during NIR laser irradiation. 31-36 A synergistic combination of two drugs as a 
promising strategy to overcome undesirable toxicity and other side effects that limit 
the utility of many potential drugs is demonstrated.37-39 Co- delivery systems, 
containing different drugs loaded into it can simultaneously deliver the drugs to the 
tumor cells, and have been proposed to minimize the amount of drug used, while 
achieving synergistic therapeutic effect in treating cancers.40, 41 PTX and DOX are 
drugs with different anticancer mechanisms.42, 43, 44 DOX is a hydrophilic compound, 
which binds to DNA by intercalation and induces a series of biochemical events 
inducing apoptosis in a number of different tumor cells. 45 PTX, a naturally occurring 
antimitotic agent, is a highly hydrophobic drug, which can inhibit microtubule 
disassembly and promote the formation of unusually stable microtubules, thereby 
disrupting normal dynamic reorganization of the microtubule network required for 
mitosis and cell proliferation, and in turn causing apoptosis. 46 Clinical studies have 
shown that the incorporation of DOX and PTX increases tumor regression rates 
relative to the individual drugs and has been used as a first-line treatment for 
metastatic breast cancer. 42 
In this report, a targeted drug delivery system for cancer chemotherapy based on 
single walled carbon nanotubes functionalized with PEG (SWCNT-PEG) and 
conjugated to folate as a targeting moiety and loaded with the commonly used potent 
chemotherapy drugs, (PTX) and DOX, to produce a DOX-PTX-FA-PEG-SWCNT 
conjugate was developed. Here, a co-delivery strategy has been proposed to minimize 
the amount of each drug and to achieve the synergistic effect for breast cancer 
therapy. Studies on drug release and cellular uptake of the co-delivery system 
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demonstrated that both drugs were effectively taken up by the breast cancer cells and 
suppressed tumor cells growth more efficiently than the individual delivery of either 
DOX or PTX at the same concentrations, indicating a synergistic effect. SWCNTs 
have a strong optical absorbance in the near-infrared (NIR) region. These optical 
properties of SWCNTs provide an opportunity for selective photothermal ablation for 
cancer treatment. In our in vitro experiments, laser effect was combined with DOX-
PTX-FA-PEG-SWCNT conjugates and an enhanced killing of breast cancer cells was 
observed. 
 
Experimental details 
Paclitaxel and Doxorubicin Hydrochloride were obtained from Wako Chemicals 
(Osaka, Japan). The SWCNTs (length 0.5-100 µm, diameter of 1-2 nm), DSPE-
PEG2000-NH2-FA (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene 
glycol-2000) folate) were obtained from Sigma Aldrich, Japan. Concentrated acids 
and all other reagents used were supplied from Fisher Scientific (Fairlawn, NJ). Cell 
cultures chemicals - Lyso-tracker, Trypan Blue, Trypsin (0.25%), Dulbecco’s 
modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) was purchased 
from Sigma-Aldrich, USA and Gibco, Japan. Invitrogen, USA, supplied Alamar Blue 
stain. All chemicals used for this work were of reagent grade. 
Purification of SWCNTs 
Purification of SWCNTs was carried out according to an already reported 
procedure47. The SWCNTs (30 mg) were added to a solution containing 96% H2SO4 
and 70% HNO3 (3:1, V/V; 120 mL) and subjected to sonication at 0˚C for 24 h. Then 
extensive washing of the SWCNTs with deionized water was carried out and filtered 
through a microporous filtration membrane (0.22 µm). After filtration, they were 
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redispersed in HNO3 (2.6 M, 200 mL) and refluxed for 24 h, and collected by 
filtration and washed with ultrapure water to neutrality. The obtained product was 
then dried at 50°C for 24 h. 
Preparation of PEGylated SWCNTs 
Purified SWCNT (0.2 mg) was sonicated in (0.10 mL) of dimethyl formamide (DMF) 
for 2 h to give a homogenous suspension. Oxalyl chloride (0.008 mL) was added drop 
wise to the purified SWCNT suspension at 0˚C under N2 atmosphere. The mixture 
was stirred at 0˚C for 2 h and then at room temperature for another 2 h. Finally, the 
temperature was raised to 70˚C and the mixture was stirred overnight on a magnetic 
stirrer to remove excess oxalyl chloride. Folate conjugated PEG (FA-PEG) dispersed 
in chloroform and methanol was used for bio-conjugation. FA-PEG (0.2 mM) was 
added to the SWCNT suspension and the mixture was stirred at 100˚C for 5 days. 
After it was cooled to room temperature, the mixture was filtered through a 0.2 µm 
pore-size membrane and washed thoroughly with ethyl alcohol and deionized water 
DI water. The PEGylated SWCNTs were collected on the membrane and dried 
overnight under vacuum48. 
Formulation of drug loaded PEGylated SWCNTs 
SWNTs (300 nmol/L, 0.05 mg/mL) with PEG-NH2 functionalization were reacted 
with 0.3 mmol/L of the modified PTX (dissolved in DMSO) in the presence of 5 
mmol/L 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 5 
mmol/L N-hydroxysulfo- succinimide (Sulfo-NHS). The solution was supplemented 
with PBS (Phosphate buffered saline) at pH 7.4. After 6 h reaction, the resulting 
SWCNT-PTX was purified to remove unconjugated PTX by filtration through 5 kDa 
molecular weight cut off filters and followed by extensive washing.49 
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DOX loaded PEGylated nanotubes were prepared for anticancer treatment. The drug 
loading efficiency and its release profile from the PEGylated nanotubes were studied. 
Dox hydrochloride (15 mg) was stirred with the PEGylated nanotubes (5 mg) 
dispersed in a PBS buffered solution of pH 7.4 (10 mL) and stirred for 16 h at room 
temperature in dark condition to synthesize the targeted drug delivery system (DOX-
FA-PEG-SWCNTs). Unbound excess DOX was removed by repeated centrifugation 
and washing with water until the filtrate was no longer red (red color corresponds to 
free DOX). Then, the resulting DOX-FA-PEG-SWCNT complexes were finally 
centrifuged at 12,000 rpm for 10 min, the supernatant was decanted and the DOX-FA-
PEG-SWCNT complexes were freeze dried50. 
Particle characterization studies 
Particle morphology of pristine and purified SWCNTs was characterized using field 
emission transmission electron microscope (TEM)(JEM 2200 FS, JEOL, Japan). One 
drop of nanotube suspension was placed on carbon coated copper grid after 
hydrophilizing the grid for 30 seconds in TEM grid hydrophilizer (JEOL DATUM, 
HDT-400) and dried thoroughly. The prepared product was analyzed under TEM, and 
tubular nature of the SWNTs was observed. The shape and surface morphology of 
both pristine and purified nanotubes were analyzed using a high-resolution scanning 
electron microscope (SEM) (JSM-7400F, JEOL, Japan) at an accelerating voltage of 
3-5 kV. For atomic force microscopy (AFM) (Asylum Research, MFP-3D-CF AFM),  
the sample was deposited on a glass surface and vacuum dried. The sample was 
characterized under tapping mode. The presence of FA-PEG on FA-PEG-SWCNT 
was confirmed from the surface chemistry analyzed by X-ray photoelectron 
spectroscopy (XPS) (AXIS His-165 Ultra, Kratos Analytical, Shimadzu Corporation, 
Japan). Five microliters of the sample was applied on a clean silicon substrate and 
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dried in vacuum. The zeta potential (Zetasizer Nano, Malvern Instruments Ltd) of 
pristine SWCNT, purified SWCNT and PEGylated SWCNT was studied to 
understand the change in their surface potential due to bio functionalization. The PTX 
and DOX conjugation to the PEGylated SWCNTs was determined by UV/Vis 
absorption spectrophotometry (Shimadzu UV-3100). 
Drug loading and in vitro release studies 
Initially, a standard curve was plotted using a series of standard paclitaxel and 
doxorubicin solutions in PBS, to facilitate the determination of the exact amount of 
the drugs loaded onto the nanotubes. The amount of drug (paclitaxel and doxorubicin) 
loaded onto the nanotubes was quantified spectrophotometrically with the help of UV/ 
Vis absorption spectrometer at an absorbance of 227 nm for paclitaxel and at 490 nm 
for doxorubicin.51, 52, 53 100 µL of the drug-loaded samples were drawn before and 
after centrifugation, to calculate the amount of DOX loaded onto the nanotubes and 
the loading efficiency of the drug used. The following formulae were used for the 
calculations: 
(1) 
 
             (2)                        
 
Where, A total drug is the initial drug concentration and A free drug is the free drug 
concentration in the supernatant. 
 
Later, the in vitro drug release profile of PTX from PTX-PEG-SWCNT, DOX from 
DOX-PEG-SWNT, and PTX and DOX from PTX-DOX-PEG-SWCNT conjugates, 
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were studied at the physiological temperature of 37°C and pH of 7.4, and 4.0 in PBS. 
Drug loaded particles (1 mg) were dissolved in PBS (5 ml) and maintained at 37°C 
under continuous shaking at 100 rpm for 3 days. At particular time intervals, 1 mL of 
the sample in buffer was taken, centrifuged and the concentration of released PTX 
and DOX in the supernatant was estimated by UV/Vis spectrophotometer at 227 nm 
and 490 nm, respectively. An equal volume of fresh PBS was replaced in the above 
suspension to maintain the sink conditions. All experiments were performed in 
triplicates. 
Cell culture studies 
Breast adenocarcinoma cells (MCF7) and mouse connective tissue (L929) fibroblast 
cells were procured from RIKEN Bioresource Center, Japan. Breast cancer cell lines 
(MCF7) and mouse fibroblast cell lines (L929) were cultured in T25 flasks and 
maintained separately in monolayers to 80% confluency in DMEM, supplemented 
with 10% FBS and 1% penicillin-streptomycin solution in a 5% CO2 humidified 
atmosphere at 37 °C.  For use in experiments, the respective cells were trypsinized, 
counted and loaded onto their respective plates for testing. Cells were seeded into 96 
well plates for cytotoxic studies and in 33 mm glass base dish for confocal studies. 
For cytotoxicity studies, 5000 cells per well were seeded and grown for 24 h and for 
confocal studies, 30,000 cells per glass base dish were plated also grown for 24h 
before treating them with the modified nanotubes. 
Cellular imaging studies 
The internalization of PTX-DOX-FA-PEG-SWCNT and PTX-DOX-PEG-SWCNT 
with cancer MCF7 and control L929 cells was investigated by confocal laser scanning 
microscopy (CLSM). MCF7 and L929 cells were seeded in a 35 mm glass based dish 
at a density of 1.6 X 104 cells/mL. The plates were incubated at 37°C and grown to 
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70% confluency. PTX-DOX-FA-PEG-SWCNT and PTX-DOX-PEG-SWCNT at 
concentration of 0.1 mg/mL were added to the cells and again incubated for 3 h, 
rinsed with PBS, and stained with Lysotracker as per the instructions of the 
manufacturer, to mark the location of lysosomes. Nanotubes gain entry into the cells 
by means of endosome-mediated transport. The cells were again washed and placed in 
fresh cell medium, viewed and imaged. 
In vitro cell viability studies 
The cell viability of PTX-FA-PEG-SWCNT, DOX-FA-PEG-SWCNT and PTX-
DOX-FA-PEG-SWCNT in comparison with free PTX and free DOX were studied by 
means of Alamar Blue assay. MCF7 cells were exposed to three different 
concentrations (0.1, 0.5 and 1.0 mg/mL) of the above five samples for 72 h. 
Experiments were conducted in triplicates. The alamar blue assay evaluates the 
proliferation and metabolic activity of cells. In living cells, the mitochondrial 
reductase enzymes are active and reduce Alamar blue to form a different colored 
product form the blue dye. This reducing ability of the cells explains the active 
metabolism that takes place within the cells. When the samples added to the cells are 
toxic in nature, the reducing ability of the cells to reduce the dye decreases. The 
fluorescence intensity of Alamar blue assay was quantified at 590-620 nm to 
determine the cell viability. 
The percentage of cell viability was calculated using the following formula: 
 
where,  is the absorbance of the sample used and  is the 
absorbance of control sample used. 
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Cancer destruction using the NIR effect of SWCNTs 
In this study, the combined destructive effect of dual drug delivery system (PTX-
DOX-FA-PEG-SWCNT) along with the effects of laser was also studied. SWCNTs 
can act efficiently to convert the 800 nm laser energy into heat to destroy target cells. 
The effect of NIR laser was studied using MCF7 cancer cell lines. Untreated cells 
were used as controls. Cells were seeded at a density of 1.6 X 104 cell/mL in 35 mm 
petri dishes. After 24 h of growth, MCF7 cells, with PTX-DOX-FA-PEG-SWCNT at 
concentration of 0.1 mg/mL were added to the cells and again incubated for 3 h, 
rinsed with PBS, and stained with Lysotracker as per the instructions of the 
manufacturer, to mark the location of lysosomes. The cells were again washed and 
placed in fresh cell medium and irradiated by 800 nm laser at 0.5-1 W/cm2 for 3 min. 
All the experiments were conducted at room temperature. The cells were viewed 
under a confocal microscope before and after laser treatment using a 100X oil 
objective and 488/561 nm excitations.  
Cytotoxicity assays of nanotubes under laser irradiation in vitro studies 
The in vitro cytotoxicity profile of the MCF7 cells with PTX-DOX-FA-PEG-SWCNT 
after laser irradiation was studied using Alamar Blue assay. MCF7 cells were exposed 
to concentration of 0.1 mg/mL for the above sample for 72 h duration. Untreated cells 
were used as controls. Experiments were conducted in triplicates. The fluorescence 
intensity of Alamar blue assay was quantified at 590-620 nm. 
 
Results and Discussions  
In this chapter, we describe a dual drug delivery system using anticancer drugs 
paclitaxel and doxorubicin, conjugated to PEGylated SWNTs, was synthesized. 
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Particle characterization analysis 
TEM, SEM and AFM were used for the surface morphology characterization of the 
purified nanotubes. On TEM and SEM observations, we found that the purified 
nanotubes were well dispersed and in small bundles as compared to the pristine 
SWCNTs, which were bundled or aggregated with black metal catalyst and 
amorphous carbon particles. We also observed a decrease in the concentration of 
metal particles and amorphous carbon in the purified nanotubes when compared to 
pristine SWCNTs (Figure 1, 2).  
  
Figure 1. Transmission electron microscopy (TEM) images of (a, b) pristine and (c, 
d) purified SWCNTs. 
  
Figure 2. Scanning electron microscopy (SEM) image of (a) pristine and (b) purified 
SWCNTs. 
a	   b	  
a	   b	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Figure 3. Atomic force microscopy (AFM) image of PEGylated SWCNTs. 
 
AFM was used to analyze the effect of PEGylation on the morphology of SWCNTs. 
We observed uniformly distributed and well dispersed PEGylated SWCNTs. (Figure 
3). 
To investigate the uniformity of the PEGylation process, we measured the zeta 
potential of the pristine, purified and PEGylated nanotubes. The zeta potential 
measures the potential at the interface between a solid surface and the liquid medium.  
Particles Zeta Potential 
Pristine SWCNT -22.7 mV 
Purified SWCNT -53.6 mV 
PEGylated SWCNT -30.1 mV 
 
Table 1. Zeta potential analysis of pristine, purified and PEGylated SWCNTs  
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The pristine SWCNT has a zeta potential of (-22.7 mV). The zeta potential has an 
increase of (-53.6 mV) for purified SWCNTs and this may be due to the existence of 
many COO- groups on the sidewalls of SWCNTs. 54 A change in the zeta potential to 
(-30.1 mV) was observed for PEGylated nanotubes. PEGylated SWCNTs has less 
negative potential than purified SWCNTs since the PEGylation converts the 
carboxylic acid groups into esters.48 Table 1 shows the zeta potential shift for 
different samples. The shift towards more negative potential for PEGylated SWCNTs 
clearly proves the proper conjugation of PEG moieties on to the SWCNTs. 
Electron Spectroscopy for Chemical Analysis (ESCA) was used to analyze the surface 
elemental compositions of the oxidized SWCNTs. The attachment of FA-PEG to 
oxidized SWCNTs was confirmed by nitrogen peak. The wide spectrum obtained 
clearly shows the peaks corresponding to carbon, oxygen and nitrogen. Nitrogen peak 
is absent in oxidized SWCNTs and the presence of nitrogen peak in the PEGylated 
SWCNTs 55 confirms the PEGylation of the oxidized SWCNTs with the PEG (Figure 
4). 
Drug loading and drug release studies 
The amount of drug (PTX and DOX) loaded onto the nanotubes was quantified 
spectrophotometrically by UV/Vis absorption spectroscopy by obtaining the 
absorption values of standard drug concentrations and correlating them. The loading 
efficiency of paclitaxel and doxorubicin was 53% and 59% respectively. The drug 
release behavior of PTX and DOX from DOX-PTX-FA-PEG-SWCNT was examined 
at 37°C in PBS at two different pH conditions - 7.4 and 4.0, respectively, with a 
continuous shaking of 100 rpm for 72 h.  
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Figure 4. X-ray photoelectron spectroscopy (XPS) peaks of SWCNTs. Inset 
correspond to N1s signal spectra of PEGylated SWCNTs that has been shown 
separately outside. 
 
The drug release curves (Figure 5, 6) reveal that the release of both the drugs (PTX 
and DOX) from the PEGylated nanotubes is markedly influenced by the pH value. 
When the pH is higher (pH 7.4), the release rate is slower. As the pH value is 
decreased (pH 4.0), the release rate is accelerated. 
The release behavior of PTX from DOX-PTX-FA-PEG-SWCNT at pH 7.4 showed a 
short-term release behavior in 8 h although the initial release rates were greater 
between 0 and 8 h, no initial burst of PTX was observed. After 8 h, the release rates 
were much lower, with very minimal drug release up to 72 h. In case of DOX released 
from DOX-PTX-FA-PEG-SWCNT under pH 7.4, an initial burst of drug release is 
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seen in 4 h, followed by a very slow rate of drug release for 6 h and then sustained 
drug delivery behavior in the following hours with very minimal drug release up to 60 
h before reaching the stationary phase. An enhanced drug release profile of PTX was 
observed at pH 4.0 within the same time period of 8 h. We observed an initial burst of 
drug release within 24 h, followed by a more sustained release of the drug till 54 h. 
For DOX at pH 4.0, an initial burst of drug release up to 6 h, followed by a sustained 
release pattern till 72 h was observed. In addition, similar release profiles obtained 
from both PTX and DOX indicated that the co-delivery system provided a synergistic 
effect. The above results can be ascribed to the hydrogen-bonding interaction between 
DOX and SWCNT which is stronger under neutral conditions, resulting in a 
controlled release.55, 56 However, under acidic conditions, the drug release pattern 
shows higher amount of DOX release, as the amine (-NH2) groups of DOX get 
protonated resulting in the partial dissociation of hydrogen-bonding interaction; 
hence, the DOX released from SWCNTs is much higher. This efficient loading and 
release of DOX indicates strong π-π stacking interaction between SWCNT and DOX. 
However, the drug release pattern for paclitaxel can be due to the hydrolysis of ester 
bonds to release paclitaxel in phosphate-buffered solutions.53 
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Figure 5. In vitro drug release profile of PTX and DOX from DOX-PTX-FA-PEG-
SWCNT in phosphate buffered saline at pH 7.4. 
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Cellular imaging studies 
To confirm the cellular uptake of the nanotubes and their localization within the cells, 
confocal laser scanning microscopy was performed. As shown in the Figure 7(a-c) 
and (d-f), the images confirm the accumulation of nanotubes within the lysosomes 
after 3 h of incubation with MCF7 cancer cells. The amount of DOX-PTX-PEG-
SWCNTs accumulated within the MCF7 cells was less as observed by the low 
fluorescence intensity in the cancer cells, as compared to the folate targeted nanotubes 
DOX-PTX-FA-PEG-SWCNTs which showed a very strong fluorescence intensity in 
the cancer cells, indicating the significant role of folate in endosomal mediated cell 
uptake. Folate-negative L929 cells were used as a control. No fluorescence was 
observed in the nucleus of all the cells, which had taken up SWCNTs, indicating that 
no SWCNTs were translocated into the nucleus. To further confirm the endosome-
mediated pathway of the nanotubes, lysosomal staining was performed using 
Lysotracker dye. The overlapping signals of red from the DOX-FA-PEG-SWCNT 
and green from lysosomes confirm the receptor-mediated endosomal uptake of the 
nanotubes into the cells. 
In vitro cell viability studies 
To study the enhanced drug effect brought about by the increased cellular uptake of 
the nanotubes due to folate conjugation in comparison with free PTX and free DOX, 
time dependent in vitro cytotoxicity assays were performed.  
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Figure 7. Confocal laser microscopy (CLSM) images showing the selective 
internalization of SWCNTs by L929 and MCF7 cells (a, d) Bright field images of the 
cells treated with nanotubes, (b, e) green fluorescence of the lysosomal staining of the 
cells with lysotracker dye, (c, f) red fluorescence of DOX conjugated nanotubes 
internalized in the cells. 
 
The tumor cells were treated with DOX-PTX-FA-PEG-SWCNTs, PTX-FA-PEG-
SWCNTs, DOX-FA-PEG-SWCNTs, free PTX and free DOX for 72 h. The assays 
were performed in triplicate. Three different concentrations of each of the above test 
samples were used. The percentage of cell viability measured for each of the samples 
was calculated using Alamar blue assay. As shown in Figure 8, co-delivery of PTX 
and DOX significantly reduced cell viability. Free single drug and single drug-loaded 
nanotubes induced similar cytotoxicity, demonstrating that the triggering mechanism 
for the release of the drug from the endosomes/lysosomes into the cytosols is highly 
efficient. Moreover when compared to single drug loaded nanotubes, the nanotubes 
a 
d 
b c 
e f 
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with dual drug (PTX- DOX) loaded showed the highest anti-tumor activity in the 
tumor cells. It is suggested that the synergistic effect might result from the 
combination of individual anti-tumor mechanism for each drug. DOX binds to DNA 
by intercalation, and motivates a series of biochemical events inducing apoptosis in 
tumor cells, and PTX can inhibit microtubules disassembly and promote the 
formation of unusually stable microtubule, thereby disrupting normal dynamic 
reorganization of the microtubule network required for mitosis and cell proliferation, 
and in turn causing cell apoptosis. Treating cancer cells using PTX and DOX together 
might achieve the best synergistic effects and accelerate tumor cell death with the 
highest anti-tumor efficacy. 
Cancer destruction using the NIR effect of SWCNTs 
The effect of SWCNTs on cancer cells during NIR laser treatment was investigated. 
MCF7 cells were incubated with DOX-PTX-FA-PEG-SWCNTs and DOX-PTX- 
PEG-SWCNTs for 3 h, followed by irradiation with an 800 nm laser for 3 min. Figure 
9 shows the confocal images of MCF7 cells treated with DOX-PTX-FA-PEG-
SWCNT before and after laser irradiation. The breaking of cancer cells due to the 
hyperthermia effects of SWNTs inside the cells can be observed and all cancer cells 
show distorted morphology of cells undergoing apoptosis. Figure 10 shows the 
confocal images of MCF7 cells treated with DOX-PTX-PEG-SWCNTs before and 
after laser irradiation. The images showed that the cells survived even after 3 min of 
laser exposure, which might be attributed to the low uptake of DOX-PTX-PEG-
SWCNTs into the MCF7 cells, confirming the significant role of folate in the 
enhanced drug delivery to the tumor cells. 
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Figure 8 (a, b). A three-day cytotoxicity assay of  (a) plain PTX and (b) plain DOX 
on MCF7 cells. 
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Figure 8. Results of cytotoxicity assay (a) 3 days study of plain PTX and plain DOX 
on MCF7 cells. 
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concentrations of each of the above test samples were used. The percentage of cell 
viability measured for each of the samples was calculated using Alamar blue assay. 
As shown in Figure 8 and 9, co-delivery of PTX and DOX significantly reduced cell 
viability. Free single drug and single drug-loaded nanotubes induced similar 
cytotoxicity, demonstrating that the triggering mechanism for the release of the drug 
from the endosomes/lysosomes into the cytosols is highly efficient. Moreover when 
compared to single drug loaded nanotubes the nanotubes with dual drug PTX/DOX 
loaded showed the highest anti-tumor activity to the tumor cells. It is suggested that 
the synergistic effect might result from the combination of individual anti-tumor 
mechanism for each drug. DOX binds to DNA by intercalation and motivates a series 
of biochemical events inducing apoptosis in tumor cells, and PTX can inhibit 
microtubules disassembly and promote the formation of unusually stable 
microtubules, thereby disrupting normal dynamic reorganization of the microtubule 
network required for mitosis and cell proliferation, and in turn causing cell apoptosis. 
Treating cancer cells using PTX and DOX together might achieve the best synergistic 
effects and accelerate tumor cell death with the highest anti-tumor efficacy. 
 
a 
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Figure 8 (c, d, e). A three-day of cytotoxicity assay of (a) PTX-FA-PEG-SWCNT, 
(b) DOX-FA-PEG-SWCNT and (c) PTX-DOX-FA-PEG-SWCNT on MCF7 cells. 
e 
!  Chapter 5 !!
! 146!
 
SWCNT + DOX 
 
SWCNT + PTX + DOX 
Figure 9. Results of cytotoxicity assay (a) 3 days study of PTX-FA-PEG-SWCNT, 
DOX-FA-PEG-SWCNT and PTX-DOX-FA-PEG-SWCNT on MCF7 cells. 
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The combined cytotoxic effect of laser and DOX loaded SWCNTs on cancer cells 
were further analyzed by Alamar blue assay. DOX-PTX-FA-PEG-SWCNTs + laser 
and DOX-PTX-PEG-SWCNTs + laser were incubated with MCF7 cells. Untreated 
cells were used as controls. All cells were irradiated with 800 nm laser for 3 mins. 
The experiments were carried out for 48 h. As shown in Figure 11, in case of cells 
treated with DOX-PTX-FA-PEG-SWCNTs a decreased rate of cell viability was 
observed. However, the cell viability rate was high for DOX-PTX-PEG-SWCNTs. 
This indicated that the targeted nanotubes were highly specific to folate receptors 
overexpressed in MCF7 cells. 
 
 
 
Figure 9. Confocal images of MCF7 cells treated with DOX-PTX-FA-PEG-SWCNT 
(a) before laser treatment (b) after 3 min laser treatment and viewed after 24 h. 
a 
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Figure 10. Confocal images of MCF7 cells treated with DOX-PTX-PEG-SWCNT (a) 
before laser treatment (b) after 3 min laser treatment and viewed after 24 h. 
 
a 
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Figure 11. Results of cytotoxicity assay of DOX-PTX-FA-PEG-SWCNT and DOX-
PTX-PEG-SWCNT after 3 min laser irradiation by an 800 nm laser on MCF7 cells. 
 
Conclusion 
We have synthesized a targeted carrier by combining the merits of PEGylated 
SWCNTs and further functionalized these nanotubes with tumor specific folate 
receptors to co-deliver PTX and DOX for pH responsive drug release in tumor 
therapy. These nanotubes possessed a high drug-loading yield. The releases of PTX 
and DOX at neutral pH were slow and sustained, however the drug releases were 
much faster in acidic environment. Studies on drug release and cellular uptake of the 
co-delivery system demonstrated that both drugs were effectively taken up by the 
cells and released simultaneously. Furthermore, the co-delivery nanocarrier 
suppresses tumor cells growth more efficiently than the individual delivery of either 
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PTX or DOX at the same concentrations, indicating a synergistic effect. Also, due to 
the presence of folate, efficient cellular targeting of the tumor cells was exhibited by 
the nanotubes that resulted in enhanced cytotoxicity in the selected tumor cells, 
avoiding toxicity to normal cells. 
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Chapter 6 
Nano-carriers for therapeutic applications 
Introduction 
Nanotechnology has been exploited extensively to enhance the pharmacokinetic 
properties and therapeutic index of myriad of drugs. The therapeutic advantages of 
nanotechnology-derived drug delivery over current treatment modalities include 
lower drug toxicities improved bioavailability, reduced cost of treatment and 
increased patient adherence to treatment. Due to advantages of targeted drug delivery 
systems enhanced cytotoxicity in selected tumor cells, with minimal cytotoxicity to 
normal cells can be achieved. Thus enhancing the therapeutic efficacy of cancer 
therapy. 
AS1411 Aptamer tagged PLGA-Lecithin- PEG nanoparticles for tumor cell 
targeting and drug delivery 
Liposomes and polymers are widely used as drug carriers for controlled release, since 
they offer many advantages like increased treatment effectiveness, reduced toxicity 
and bio-degradability. In this work, anticancer drug loaded PLGA –lecithin-PEG 
nanoparticles were synthesized and were functionalized with AS1411 Anti-nucleolin 
aptamers for site specific targeting against tumor cells, which overexpresses nucleolin 
receptors. Drug loading studies indicated that under the same drug loading, the 
aptamer-targeted nanoparticles show enhanced cancer killing effect when compared 
to the non- targeted nanoparticles. In addition, the PLGA-lecithin-PEG nanoparticles 
exhibited high encapsulation efficiency and superior, sustained drug release than the 
drug loaded in plain PLGA nanoparticles. The results confirmed that AS1411 
aptamer-PLGA-lecithin-PEG nanoparticles are potential carrier candidates for 
differential targeted drug delivery. 
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Chapter 7 
Conclusion and future prospects 
Nanotechnology has great potential in developing efficient cancer therapeutics. We 
have synthesized CNT encapsulated chemotherapeutic agents and targeted it for site- 
directed drug delivery. In this final chapter, we are presenting the major observations 
of our work. 
1. Nano delivery systems hold great potential to overcome many of the present 
obstacles of drug delivery. Carbon nanotubes have been proposed and actively 
explored as multipurpose innovative carriers of drugs for drug delivery and diagnostic 
applications. They have many unique physical, mechanical and electronic properties, 
and these distinct and exceptional properties have made it possible to exploit CNTs as 
drug delivery systems for biomedical applications. CNTs are promising carriers of 
both small drug molecules as well as macromolecules such as genes and proteins. 
Functionalization of CNTs with an organic moiety has made possible their use in 
diagnostics for imaging as well as for targeting purposes, especially in cancer therapy. 
Nanotube drug delivery holds future promise for high treatment efficacy with low 
drug doses, combined with minimal side effects for cancer therapy.  
 Even though CNTs are playing a larger and most promising role in the field of nano-
medicine, more research is required to guarantee safety in drug delivery. 
Functionalized CNTs have been considered biocompatible and safe for drug and bio-
molecular delivery applications, as they are soluble in physiological media and are 
nontoxic. They have shown no accumulation in the tissues and can be readily excreted 
through the renal route. Toxicity studies are critical to establish the full in vivo 
potential of CNTs for drug delivery before their actual application and marketing. In 
order to understand the toxic impact of the systemic delivery of carbon nanotubes in 
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greater detail, more extensive toxicity, safety and efficacy studies in animal models 
and in humans over a longer time frame need to be performed. The effects of CNT 
aggregation, size, length, functionalization, metal impurities on the toxicological 
safety require more thorough research. Functionalization of SWCNTs and its effects 
on aggregation and consequent genotoxicity also needs to be evaluated. Overall, the 
use of CNTs for delivery of drugs and biomolecules is a significant development in 
the field of therapeutic nano-medicine. 
2. We successfully synthesized a highly effective targeted NDDS based on PEG 
functionalized SWCNTs and then further functionalization was facilitated with a 
targeting group (FA) and an anticancer drug (Doxorubicin). The obtained system 
(DOX-FA-PEG-SWCNT) displays excellent stability under physiological conditions. 
It was found that it could also effectively release DOX at reduced pH typical of the 
tumor environment of intracellular lysosomes and endosomes. We conclude that this 
nanoscale drug delivery system is more selective and effective than the free drug and 
it should result in enhanced therapeutic effects, with reduced general toxicity and 
hence reduced side effects in patients. Considering these positive in vitro drug 
delivery results, the application of DOX-FA-PEG-SWCNT could be extended to 
enhance the efficiency of cancer therapy in vivo. 
3. With this obtained system- (DOX-FA-PEG-SWCNT), we further demonstrate a 
photothermal technique for targeted cancer destruction by using the photothermal 
effect of SWCNTs. SWCNTs has a high optical absorbance in the NIR region, where 
biological tissues are highly transparent. From the observation of our data, it is clear 
that SWCNTs act efficiently to convert laser energy into heat after exposure to 800 
nm laser irradiation in vitro. This advantage was used in selective photothermal 
therapy, for killing only cancer cells while sparing normal cells. Our results also 
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showed that both, concentration of SWCNTs and time of laser, are controlling factors 
for thermally induced cytotoxicity. Also, the combined effect of targeted drug loaded 
DOX-FA-PEG-SWCNT with photothermal therapy was studied and we observed that 
the combined effect synergistically killed almost 95% of cancer cells at an accelerated 
rate. We conclude that this nanoscale drug delivery system is more selective and 
effective than the free drug, and results in enhanced therapeutic effects, when 
combined with photothermal therapy and reduced general toxicity. Considering these 
promising in vitro drug delivery results, the application of DOX-FA-PEG-SWCNT 
combined with NIR laser could be extended to enhance the efficiency of cancer 
therapy in the near future. 
4. We have synthesized a targeted carrier by combining the merits of PEGylated 
SWCNTs and further functionalizing these nanotubes with tumor specific folate 
receptors to co-deliver PTX and DOX for pH responsive drug release in tumor 
therapy. These nanotubes possessed a high drug-loading yield. The releases of PTX 
and DOX at neutral pH were slow and sustained, however the drug releases were 
much faster at acidic environment. Studies on drug release and cellular uptake of the 
co-delivery system demonstrated that both drugs were effectively taken up by the 
cells and released simultaneously. Furthermore, the co-delivery of nano-carrier 
suppresses tumor cell growth more efficiently than by the individual delivery of either 
PTX or DOX at the same concentrations, indicating a synergistic effect. Also, due to 
the presence of folate, efficient cellular targeting of tumor cells was exhibited by the 
nanotubes, which resulted in enhanced cytotoxicity in the selected tumor cells, 
avoiding toxicity to normal cells. 
5. Anticancer drug loaded PLGA-lecithin-PEG nanoparticles were synthesized and 
were functionalized with AS1411 Anti-nucleolin aptamers for site specific targeting 
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against tumor cells, which overexpresses nucleolin receptors. Drug loading studies 
indicated that under the same drug loading, the aptamer-targeted nanoparticles show 
enhanced cancer killing effect when compared to the non- targeted nanoparticles.  
Developments of anticancerous nanoparticles have been considered as one of the 
promising therapeutic applications in the growing field of nanotechnology. Cancer 
nanotechnology exerts its application through the development of nanocarriers with 
multiple functionalities which can be targeted to tumors, and which can act as 
controlled delivery vehicles for improved therapy efficacy. These advances will 
hopefully open new pathways and innovations in the field of nanoscience and 
nanotechnology. 
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APPENDIX I 
____________________________________________________________________ 
GLOSSARY 
NDDS      Nano Drug Delivery System 
DDS                     Drug Delivery System 
TEM                 Transmission Electron Microscope 
SEM                        Scanning Electron Microscopy 
AFM                      Atomic Force Microscope 
XPS                         X-ray Photoelectron Spectroscopy 
UV-Vis                    Ultraviolet-Visible Spectrometer 
CLSM                    Confocal Laser Scanning Microscopy 
ESCA                     Electron Spectroscopy for chemical analysis 
NIR                           Near Infrared 
IR                              Infra red 
CNTs                        Carbon Nanotubes 
SWCNTs                  Single Wall Carbon Nanotubes 
MWCNTs                 Multiwall Carbon Nanotubes 
SWCNT-COOH     Carboxylic acid functionalized SWCNTs 
DOX-FA-PEG-SWCNTs  Doxorubicin and folate conjugated 
HNO3                        Nitric acid 
H2SO4                       Sulfuric acid 
NHS                        N-hydro succinimide 
DSC                        Disuccinimide carbonate 
DMF                        Dimethylformamide 
NaOH                     Sodium Hydroxide 
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 dd.H2O                Double Distilled Water 
DI                          Distilled Water 
MWCO                     Molecular weight cut off 
AB                              Alamar Blue 
FITC                        Fluorescein Isothiocyanate  
DMEM                    Dulbecco’s Minimal Essential Medium 
PBS                        Phosphate buffered saline 
FBS                         Foetal Bovine Serum 
PEG                        Polyethylene Glycol 
FA                         Folic acid 
DSPE-PEG2000-NH2 folate   1, 2-distearoyl-sn-glycero-N-carboxy (polyethylene  
    glycol)2000 aminefolate 
DOX                       Doxorubicin 
PTX                        Paclitaxel 
MCF7                Human Breast Adenocarcinoma 
L929                   Mouse Fibroblast Cells 
CO2                            Carbondioxide 
 
